menu
    • menu
    [{"orgOrder":0,"company":"Topokine Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"XAF5","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Topokine Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Gel","sponsorNew":"Topokine Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Topokine Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Veeda Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"MT-102","moa":"\n5-HT1A receptor\/Beta-adrenoceptors\/Beta2-adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Akamis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akamis Bio \/ Veeda Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Akamis Bio \/ Veeda Oncology"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"S-Pindolol Benzoate","moa":"\n5-HT1A receptor\/Beta-adrenoceptors\/Beta2-adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Series A Financing","leadProduct":"S-Pindolol Benzoate","moa":"\n5-HT1A receptor\/Beta-adrenoceptors\/Beta2-adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Mankind Pharma"},{"orgOrder":0,"company":"Biomed Industries","sponsor":"Bioneurals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NA-931","moa":"\nGCGR\/GIPR\/GLP-1R\/IGF-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biomed Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomed Industries \/ Bioneurals","highestDevelopmentStatusID":"8","companyTruncated":"Biomed Industries \/ Bioneurals"},{"orgOrder":0,"company":"Biomed Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NA-931","moa":"\nGCGR\/GIPR\/GLP-1R\/IGF-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biomed Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomed Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomed Industries \/ Undisclosed"},{"orgOrder":0,"company":"Biomed Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NA-931","moa":"\nGCGR\/GIPR\/GLP-1R\/IGF-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biomed Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomed Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomed Industries \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"MT-921","moa":"\nLipid","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MT-921","moa":"\nLipid","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"St. Antonius Hospital | Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Micafungin","moa":"1,3-beta-glucan synthase","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ St. Antonius Hospital | Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Radboud University Medical Center \/ St. Antonius Hospital | Astellas Pharma"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Micafungin","moa":"1,3-beta-glucan synthase","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UT Southwestern Medical Center \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ Astellas Pharma"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"PF-05230901","moa":"11-beta-HSD1","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AZD4017","moa":"11-beta-hydroxysteroid dehydrogenase 1","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Hebrew University of Jerusalem","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Hebrew University of Jerusalem"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"SCIRENT Clinical Research and Science d.o.o.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"(S)-Pindolol Benzoate","moa":"5-HT1A receptor | beta-adrenoceptors | beta 2-adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Actimed Therapeutics \/ SCIRENT Clinical Research and Science d.o.o.","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ SCIRENT Clinical Research and Science d.o.o."},{"orgOrder":0,"company":"Rose Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ROSE-010","moa":"5-HT4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rose Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rose Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rose Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ACM-001.1","moa":"5-HTA1a\/beta-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Actimed Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Actimed Therapeutics \/ Quotient Sciences"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"LX9851","moa":"ACSL5","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Lexicon pharmaceuticals","amount2":1,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"Lexicon pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Lexicon pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"BYM338","moa":"Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Supercede Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SPCD-4-79","moa":"Activin type-2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Supercede Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supercede Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Supercede Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"LAE102","moa":"Activin type-2A receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Laekna Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Laekna Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LAE102","moa":"Activin type-2A receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Laekna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ARO-ALK7","moa":"ACVR1C","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-ALK7","moa":"ACVR1C","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ARO-ALK7","moa":"ACVR1C","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"||Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"||Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"Bimagrumab","moa":"||Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":1.9299999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1.9299999999999999,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"Bimagrumab","moa":"||Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":1.9299999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1.9299999999999999,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Versanis Bio","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Versanis Bio","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Versanis Bio"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Pennington Biomedical Research Center","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Pennington Biomedical Research Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pennington Biomedical Research Center \/ Amgen Inc","highestDevelopmentStatusID":"1","companyTruncated":"Pennington Biomedical Research Center \/ Amgen Inc"},{"orgOrder":0,"company":"Oregon Weight Loss Surgery, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Oregon Weight Loss Surgery, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oregon Weight Loss Surgery, LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Oregon Weight Loss Surgery, LLC \/ Undisclosed"},{"orgOrder":0,"company":"PLT Health Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"PLT Health Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PLT Health Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PLT Health Solutions \/ Undisclosed"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sulfiram","moa":"Aldehyde dehydrogenase","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"National Institute on Aging","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Aging \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Aging \/ Undisclosed"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Your Energy Systems, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Liposomal Glutathione","moa":"Aldo-keto reductase family 1 member B1; Matrix metalloproteinase-9; Cytochrome P450 3A4; Glutathione peroxidase; Glutathione reductase, mitochondrial; Glutathione synthetase; Glutathione S-transferase Mu 1; Glutathione S-transferase kappa 1; Glutathione S-transferase A3; Glutathione S-transferase Mu 3; Glutathione S-transferase A4; Glutathione S-transferase Mu 4; Glutathione S-transferase A5; Glutathione S-transferase P; Glutathione S-transferase omega-1; Glutathione peroxidase 1; Glutathione peroxidase 2; Glutathione S-transferase theta-1; Maleylacetoacetate isomerase; Epididymal secretory glutathione peroxidase; Glutathione peroxidase 3; Lactoylglutathione lyase; Leukotriene C4 synthase; Glutathione S-transferase 3, mitochondrial; Hematopoietic prostaglandin D synthase; Glutathione S-transferase A1; Glutathione S-transferase A2; Microsomal glutathione S-transferase 1; S-formylglutathione hydrolase; Glutathione hydrolase 1 proenzyme; Glutathione S-transferase Mu 2; Glutaredoxin-1; Pho","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Your Energy Systems, LLC","highestDevelopmentStatusID":"1","companyTruncated":"Gabrail Cancer Center Research \/ Your Energy Systems, LLC"},{"orgOrder":0,"company":"TargEDys","sponsor":"Inoliva","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Hafnia alvei HA4597","moa":"Alpha-MSH","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"TargEDys","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TargEDys \/ Inoliva","highestDevelopmentStatusID":"15","companyTruncated":"TargEDys \/ Inoliva"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Clarke Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series A Financing","leadProduct":"MLX0800","moa":"AMPK","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biolexis Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Biolexis Therapeutics \/ Clarke Capital","highestDevelopmentStatusID":"4","companyTruncated":"Biolexis Therapeutics \/ Clarke Capital"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"Solution","sponsorNew":"OrsoBio \/ Ascenta Capital","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Ascenta Capital"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pramlintide","moa":"||Amylin receptor AMY1, CALCR\/RAMP1","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pramlintide","moa":"Amylin receptor AMY1, CALCR\/RAMP1","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Amycretin","moa":"GLP-1\/Amylin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Amycretin","moa":"GLP-1\/Amylin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Amycretin","moa":"GLP-1\/Amylin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Amycretin","moa":"AMYR","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AZD6234","moa":"AMYR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AZD6234","moa":"AMYR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AZD6234","moa":"AMYR","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Veru \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Veru \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"GSK2849466","moa":"Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"GSK2881078","moa":"Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Parexel"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"GSK2881078","moa":"Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"GSK2881078","moa":"Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Austin Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"AUSTRALIA","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Austin Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Austin Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Austin Health \/ Undisclosed"},{"orgOrder":0,"company":"nuBioAge","sponsor":"Marius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2024","type":"Collaboration","leadProduct":"Testosterone Undecanoate","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"nuBioAge","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"nuBioAge \/ Marius Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"nuBioAge \/ Marius Pharmaceuticals"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Gene PreDiT","sponsor":"Blueclinical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Perindopril","moa":"Angiotensin-converting enzyme","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Gene PreDiT","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gene PreDiT \/ Blueclinical","highestDevelopmentStatusID":"8","companyTruncated":"Gene PreDiT \/ Blueclinical"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Fleroxacin","moa":"antibacterials (quinolone derivatives)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"S.LAB (SOLOWAYS)","sponsor":"Center of New Medical Technologies | Triangel Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"RUSSIA","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Glucomannan","moa":"anti-inflammatory agents (acetic acid derivatives)","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"S.LAB (SOLOWAYS)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"S.LAB (SOLOWAYS) \/ Center of New Medical Technologies | Triangel Scientific","highestDevelopmentStatusID":"1","companyTruncated":"S.LAB (SOLOWAYS) \/ Center of New Medical Technologies | Triangel Scientific"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azelaprag","moa":"Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Eli Lilly"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azelaprag","moa":"||Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Undisclosed"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azelaprag","moa":"||Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Undisclosed"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Azelaprag","moa":"||Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Eli Lilly"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series D Financing","leadProduct":"Azelaprag","moa":"||Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.17000000000000001,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Sofinnova Investments","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Sofinnova Investments"},{"orgOrder":0,"company":"Newcastle NHS Trust","sponsor":"Newcastle University | Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Beta Carotene","moa":"arotinoid derivatives","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Newcastle NHS Trust","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Newcastle NHS Trust \/ Newcastle University | Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Newcastle NHS Trust \/ Newcastle University | Royal DSM"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Zinc","moa":"||B1 bradykinin receptor; Methylated-DNA--protein-cysteine methyltransferase; Fructose-bisphosphate aldolase A; Elongation factor 1-alpha 1; Alpha-enolase; Glyceraldehyde-3-phosphate dehydrogenase, testis-specific; Nucleoside diphosphate kinase A; Protein disulfide-isomerase; Protein disulfide-isomerase A3; Peroxiredoxin-1; Phosphoserine phosphatase; Triosephosphate isomerase; Elongation factor Tu, mitochondrial; Estrogen receptor; Interleukin-3; Metallothionein-2; Copper chaperone for superoxide dismutase; Histone deacetylase 1; Histone deacetylase 4; DNA-3-methyladenine glycosylase; Semenogelin-1; Superoxide dismutase [Cu-Zn]; Histone deacetylase 8; Apoptosis regulatory protein Siva; Glycine receptor subunit alpha-1; E3 ubiquitin-protein ligase Mdm2; Insulin; Utrophin; Aspartoacylase; Protein S100-A8; Protein S100-A9; Matrix metalloproteinase-9; Tumor protein p73; Protein S100-A2; Cellular tumor antigen p53; Metallothionein-3; Programmed cell death protein 6; DAN domain family member 5","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"Amit.Pai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Amit.Pai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Amit.Pai \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Amit.Pai \/ Merck & Co"},{"orgOrder":0,"company":"Manjunath Prakash Pai","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tigecycline","moa":"Bacterial 70S ribosome","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Manjunath Prakash Pai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Manjunath Prakash Pai \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Manjunath Prakash Pai \/ Pfizer Inc"},{"orgOrder":0,"company":"Laval University","sponsor":"Naturex","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Cranberry","moa":"Bacterial adhesion","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laval University \/ Naturex","highestDevelopmentStatusID":"1","companyTruncated":"Laval University \/ Naturex"},{"orgOrder":0,"company":"Vincentage Pharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vincentage Pharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vincentage Pharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vincentage Pharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"University of Oxford | KEMRI-Wellcome Trust Research Program | University of Washington | Wageningen University | Zvitambo Institute for Maternal & Child Health | Tropical Gastroenterology & Nutrition Group (TROPGAN) | University of Cambridge | Kenya Medi","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Queen Mary University of London \/ University of Oxford | KEMRI-Wellcome Trust Research Program | University of Washington | Wageningen University | Zvitambo Institute for Maternal & Child Health | Tropical Gastroenterology & Nutrition Group (TROPGAN) | University of Cambridge | Kenya Medi","highestDevelopmentStatusID":"10","companyTruncated":"Queen Mary University of London \/ University of Oxford | KEMRI-Wellcome Trust Research Program | University of Washington | Wageningen University | Zvitambo Institute for Maternal & Child Health | Tropical Gastroenterology & Nutrition Group (TROPGAN) | University of Cambridge | Kenya Medi"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Project Peanut Butter | Kamuzu University of Health Sciences | BALCHEM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Washington University School of Medicine \/ Project Peanut Butter | Kamuzu University of Health Sciences | BALCHEM","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Project Peanut Butter | Kamuzu University of Health Sciences | BALCHEM"},{"orgOrder":0,"company":"University of Illinois, Chicago","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Illinois, Chicago","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Illinois, Chicago \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Illinois, Chicago \/ Merck & Co"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tin Mesoporphyrin","moa":"benzoporphyrin derivatives","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Oxprenolol","moa":"Beta-2 adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neothetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Salmeterol Xinafoate","moa":"Beta-2 adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Neothetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neothetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neothetics \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Pindolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Mankind Pharma"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"Pindolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mk-3655","moa":"Beta-klotho (KLB)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Mk-3655","moa":"Beta-klotho (KLB)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APHD-012","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aphaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"APHD-012","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aphaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Carbohydrate","year":"2024","type":"Inapplicable","leadProduct":"Dextrose","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aphaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Carbohydrate","year":"2024","type":"Inapplicable","leadProduct":"Dextrose","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aphaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"NovaClin Medical Research Center S.R.L | ACC GmbH Analytical Clinical Concepts | SC Bioclinica SA | Galephar Pharmaceutical Research (PR), Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Glucose","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aphaia Pharma \/ NovaClin Medical Research Center S.R.L | ACC GmbH Analytical Clinical Concepts | SC Bioclinica SA | Galephar Pharmaceutical Research (PR), Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ NovaClin Medical Research Center S.R.L | ACC GmbH Analytical Clinical Concepts | SC Bioclinica SA | Galephar Pharmaceutical Research (PR), Inc."},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Glucose","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aphaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Pill","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Univo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Univo Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Can-Fite BioPharma \/ Univo Pharmaceuticals"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Can-Fite BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lexaria Bioscience \/ Can-Fite BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Can-Fite BioPharma"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Nabilone","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Nimacimab","moa":"||Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Skye Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Arecor \/ Skye Bioscience"},{"orgOrder":0,"company":"Beacon Biosignals","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Nimacimab","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Beacon Biosignals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beacon Biosignals \/ Skye Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Beacon Biosignals \/ Skye Bioscience"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Nimacimab","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Beacon Biosignals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Nimacimab","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Beacon Biosignals","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Beacon Biosignals"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Nimacimab","moa":"||Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Skye Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Benuvia","sponsor":"Avernus Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Benuvia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"Benuvia \/ Avernus Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Benuvia \/ Avernus Pharma"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Baymedica","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabivarin","moa":"cannabinol derivatives","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InMed Pharmaceuticals \/ Baymedica","highestDevelopmentStatusID":"1","companyTruncated":"InMed Pharmaceuticals \/ Baymedica"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Radicle Science","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabivarin","moa":"cannabinol derivatives","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InMed Pharmaceuticals \/ Radicle Science","highestDevelopmentStatusID":"15","companyTruncated":"InMed Pharmaceuticals \/ Radicle Science"},{"orgOrder":0,"company":"Baymedica","sponsor":"InMed Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cannabichromene","moa":"CB","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Baymedica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baymedica \/ InMed Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Baymedica \/ InMed Pharmaceuticals"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CRB-913","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INV-202","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Monlunabant","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Monlunabant","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Bayer AG"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Bayer AG"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"PDL BioPharma","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Divestment","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"PDL BioPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PDL BioPharma \/ SWK Holdings Corporation","highestDevelopmentStatusID":"15","companyTruncated":"PDL BioPharma \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"Altimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ALT-801","moa":"Cellular tumor antigen p53 (TP53)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Brest","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"University Hospital, Brest","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Brest \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"University Hospital, Brest \/ Bayer AG"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AZD8329","moa":"Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Florian Strasser","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Florian Strasser","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Florian Strasser \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Florian Strasser \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Insel Gruppe AG, University Hospital Bern","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1; Amidophosphoribosyltransferase; Glutamine synthetase","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Insel Gruppe AG, University Hospital Bern","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insel Gruppe AG, University Hospital Bern \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"11","companyTruncated":"Insel Gruppe AG, University Hospital Bern \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Norwegian University of Science and Technology","sponsor":"St. Olavs Hospital | Oslo University Hospital | Cantonal Hospital of St. Gallen | Ottawa Regional Cancer Centre | Jewish General Hospital | Cross Cancer Institute | The Beatson West of Scotland Cancer Centre | Queen Margaret Hospital, Dunfermline | Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NORWAY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Norwegian University of Science and Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Norwegian University of Science and Technology \/ St. Olavs Hospital | Oslo University Hospital | Cantonal Hospital of St. Gallen | Ottawa Regional Cancer Centre | Jewish General Hospital | Cross Cancer Institute | The Beatson West of Scotland Cancer Centre | Queen Margaret Hospital, Dunfermline | Cancer","highestDevelopmentStatusID":"10","companyTruncated":"Norwegian University of Science and Technology \/ St. Olavs Hospital | Oslo University Hospital | Cantonal Hospital of St. Gallen | Ottawa Regional Cancer Centre | Jewish General Hospital | Cross Cancer Institute | The Beatson West of Scotland Cancer Centre | Queen Margaret Hospital, Dunfermline | Cancer"},{"orgOrder":0,"company":"Jacobi Medical Center","sponsor":"Cumberland Pharmaceuticals | Sagatech Electronics Inc, Alberta, Canada","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Jacobi Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobi Medical Center \/ Cumberland Pharmaceuticals | Sagatech Electronics Inc, Alberta, Canada","highestDevelopmentStatusID":"11","companyTruncated":"Jacobi Medical Center \/ Cumberland Pharmaceuticals | Sagatech Electronics Inc, Alberta, Canada"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"St. Antonius Hospital | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Posaconazole","moa":"Cytochrome P450 51","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radboud University Medical Center \/ St. Antonius Hospital | Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Radboud University Medical Center \/ St. Antonius Hospital | Merck & Co"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Mead Johnson Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Mead Johnson Nutrition","highestDevelopmentStatusID":"1","companyTruncated":"University of Alabama at Birmingham \/ Mead Johnson Nutrition"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AZD7687","moa":"Diacylglycerol acyltransferase 1 (DGAT1)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"3 Waves Wellness","sponsor":"Kaneka Americas Holding Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Lactobacillus Plantarum","moa":"Dopamine receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"3 Waves Wellness","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3 Waves Wellness \/ Kaneka Americas Holding Inc.","highestDevelopmentStatusID":"1","companyTruncated":"3 Waves Wellness \/ Kaneka Americas Holding Inc."},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ARD-201","moa":"DPP-4","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aardvark Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aardvark Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"GSK2890457","moa":"Endogenous gut peptide (EGP)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"10xbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Polidocanol","moa":"Endothelium of blood vessels (Endothelium)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"10xbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"10xbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"10xbio \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"NNC0194-0499","moa":"FGF21 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"NNC0194-0499","moa":"FGF21 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Ngm395","moa":"FGFR1c\/KLB","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"ISIS-FGFR4RX","moa":"FGFR4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University Medical Centre Ljubljana","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SLOVENIA","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Corifollitropin Alfa","moa":"Follicle stimulating hormone receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University Medical Centre Ljubljana","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Centre Ljubljana \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University Medical Centre Ljubljana \/ Merck & Co"},{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Quintiles Inc | Miami Research Associates","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"P11187","moa":"Free fatty acid receptor 1 (GPR40)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Piramal Enterprises Limited \/ Quintiles Inc | Miami Research Associates","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Enterprises Limited \/ Quintiles Inc | Miami Research Associates"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"LLF580","moa":"FXR","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Bloom Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"BL-001","moa":"GABA receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Bloom Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bloom Science \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bloom Science \/ Undisclosed"},{"orgOrder":0,"company":"Pedro Paulo Tanaka","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Propofol","moa":"GABA-A receptor; anion channel","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Pedro Paulo Tanaka","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pedro Paulo Tanaka \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Pedro Paulo Tanaka \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Magnesium","moa":"GABA-B receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Undisclosed"},{"orgOrder":0,"company":"Natural Calm Canada","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Magnesium","moa":"GABA-B receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Natural Calm Canada","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Natural Calm Canada \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Natural Calm Canada \/ Nutrasource"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody-peptide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"AMG 133","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Carmot Therapeutics","amount2":3.1000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":3.1000000000000001,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Carmot Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Carmot Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Carmot Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LY3532226","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Retatrutide","moa":"Gastric inhibitory polypeptide receptor (GIPR)||GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Retatrutide","moa":"Gastric inhibitory polypeptide receptor (GIPR)||GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Retatrutide","moa":"Gastric inhibitory polypeptide receptor (GIPR)||GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Retatrutide","moa":"Gastric inhibitory polypeptide receptor (GIPR)||GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Retatrutide","moa":"Gastric inhibitory polypeptide receptor (GIPR)||GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Retatrutide","moa":"GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Retatrutide","moa":"GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Retatrutide","moa":"GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Retatrutide","moa":"GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Retatrutide","moa":"GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Retatrutide","moa":"GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Retatrutide","moa":"GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Retatrutide","moa":"GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BI456906","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"BI456906","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BI456906","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"BI456906","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"BI456906","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"DA-1726","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neuraly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"DD01","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Neuraly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuraly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Neuraly \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GCGR\/GLP-1R||GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GCGR\/GLP-1R||GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GCGR\/GLP-1R||GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GCGR\/GLP-1R||GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GCGR\/GLP-1R||GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GCGR\/GLP-1R||GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GCGR\/GLP-1R||GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GCGR\/GLP-1R||GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GCGR\/GLP-1R||GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GCGR\/GLP-1R||GLP-1|GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GCGR\/GLP-1R||Glucagon receptor (GCGR)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GCGR\/GLP-1R||Glucagon receptor (GCGR)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GCGR\/GLP-1R||Glucagon receptor (GCGR)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"OPKO Health","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnteraBio Ltd \/ OPKO Health","highestDevelopmentStatusID":"4","companyTruncated":"EnteraBio Ltd \/ OPKO Health"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MetaVia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"MetaVia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"MetaVia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MetaVia \/ Undisclosed"},{"orgOrder":0,"company":"OPKO Health","sponsor":"EnteraBio Ltd","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OPKO Health \/ EnteraBio Ltd","highestDevelopmentStatusID":"4","companyTruncated":"OPKO Health \/ EnteraBio Ltd"},{"orgOrder":0,"company":"PegBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PB-718","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"PegBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PegBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PegBio \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"HEC-007","moa":"GCGR|GIPR|GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Lake Pharma \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Lake Pharma \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ponsegromab","moa":"GDF15","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"CatalYm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Visugromab","moa":"GDF15","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CatalYm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"CatalYm \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AV-380","moa":"GDF-15","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AV-380","moa":"GDF-15","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"GB18","moa":"GDF-15","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kexing Biopharm \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Kexing Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"NGM120","moa":"GDNF family receptor alpha-like (GFRAL)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Anamorelin HCl","moa":"Ghrelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Anamorelin HCl","moa":"Ghrelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Anamorelin HCl","moa":"Ghrelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Anamorelin HCl","moa":"Ghrelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Helsinn Advanced Synthesis \/ Oberland Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ Oberland Capital Management"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Anamorelin HCl","moa":"Ghrelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Anamorelin HCl","moa":"Ghrelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Anamorelin HCl","moa":"Ghrelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Anamorelin HCl","moa":"Ghrelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"VA Office of Research and Development \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"8","companyTruncated":"VA Office of Research and Development \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Garcia, Jose M., MD, PhD","sponsor":"VA Office of Research and Development | Baylor College of Medicine | Aeterna Zentaris","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Macimorelin","moa":"Ghrelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Garcia, Jose M., MD, PhD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Garcia, Jose M., MD, PhD \/ VA Office of Research and Development | Baylor College of Medicine | Aeterna Zentaris","highestDevelopmentStatusID":"8","companyTruncated":"Garcia, Jose M., MD, PhD \/ VA Office of Research and Development | Baylor College of Medicine | Aeterna Zentaris"},{"orgOrder":0,"company":"Gelesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Gelesis100","moa":"GI tract","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Gelesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gelesis \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Gelesis \/ Undisclosed"},{"orgOrder":0,"company":"Helicore Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"HCR-188","moa":"GIP","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Helicore Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Helicore Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Helicore Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Helicore Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"HCR-188","moa":"GIP","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Helicore Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Helicore Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Helicore Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"NM-136","moa":"GIP","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NM-136","moa":"GIP","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"CordenPharma","sponsor":"Viking Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2025","type":"Partnership","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"CordenPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CordenPharma \/ Viking Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CordenPharma \/ Viking Therapeutics"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP|GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP|GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gmax Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"GMA106","moa":"GIPR","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gmax Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gmax Biopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gmax Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Gmax Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"GMA106","moa":"GIPR","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gmax Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gmax Biopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gmax Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Bofanglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bofanglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"||GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"||GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CT-868","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmot Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Carmot Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CT-868","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmot Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Carmot Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CX11","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corxel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CX11","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corxel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eccogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"ECC5004","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eccogene","amount2":2.0099999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.0099999999999998,"dosageForm":"Tablet","sponsorNew":"Eccogene \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Eccogene \/ AstraZeneca"},{"orgOrder":0,"company":"Eccogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"ECC5004","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eccogene","amount2":2.0099999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.0099999999999998,"dosageForm":"Tablet","sponsorNew":"Eccogene \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Eccogene \/ AstraZeneca"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"IDG Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Series C Financing","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ IDG Capital","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ IDG Capital"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"||GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Verdiva Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":2.4700000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.4700000000000002,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Verdiva Bio","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Verdiva Bio"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sciwind Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"Ecnoglutide","moa":"||GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Sciwind Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ Sciwind Biosciences"},{"orgOrder":0,"company":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","sponsor":"Shanghai Jiaotong University Affiliated Sixth People's Hospital | Beijing Friendship Hospital | Jinan Central Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efsubaglutide Alfa","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Shanghai Jiaotong University Affiliated Sixth People's Hospital | Beijing Friendship Hospital | Jinan Central Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Shanghai Jiaotong University Affiliated Sixth People's Hospital | Beijing Friendship Hospital | Jinan Central Hospital"},{"orgOrder":0,"company":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efsubaglutide Alfa","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efsubaglutide Alfa","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Ingrid Jazet","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Exenatide Synthetic","moa":"GLP-1 receptor||Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Ingrid Jazet","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ingrid Jazet \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Ingrid Jazet \/ AstraZeneca"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Structure Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Structure Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Structure Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Structure Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Structure Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"GZR18","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"GZR18","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"GZR18","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"GZR18","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HRS-7535","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HRS-7535","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HRS-7535","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HRS-7535","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"MindRank","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MDR-001","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"MindRank","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MindRank \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindRank \/ Undisclosed"},{"orgOrder":0,"company":"MindRank","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MDR-001","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"MindRank","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MindRank \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindRank \/ Undisclosed"},{"orgOrder":0,"company":"MindRank","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MDR-001","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"MindRank","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MindRank \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindRank \/ Undisclosed"},{"orgOrder":0,"company":"MindRank","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MDR-001","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"MindRank","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MindRank \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindRank \/ Undisclosed"},{"orgOrder":0,"company":"Metsera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Metsera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Undisclosed"},{"orgOrder":0,"company":"Metsera","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.32000000000000001,"dosageForm":"Injection","sponsorNew":"Metsera \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ BofA Securities"},{"orgOrder":0,"company":"Metsera","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0.32000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.32000000000000001,"dosageForm":"Injection","sponsorNew":"Metsera \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ BofA Securities"},{"orgOrder":0,"company":"Metsera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metsera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Undisclosed"},{"orgOrder":0,"company":"Metsera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metsera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Altimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Undisclosed"},{"orgOrder":0,"company":"Altimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Undisclosed"},{"orgOrder":0,"company":"Altimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Undisclosed"},{"orgOrder":0,"company":"Altimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Undisclosed"},{"orgOrder":0,"company":"Altimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Undisclosed"},{"orgOrder":0,"company":"Altimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Undisclosed"},{"orgOrder":0,"company":"Altimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Undisclosed"},{"orgOrder":0,"company":"Altimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Undisclosed"},{"orgOrder":0,"company":"Altimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Undisclosed"},{"orgOrder":0,"company":"Altimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Undisclosed"},{"orgOrder":0,"company":"Altimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Parexel"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"Petrelintide","moa":"||GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":5.2999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":5.2999999999999998,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Parexel"},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"RJVA-001","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Fractyl Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fractyl Health \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Fractyl Health \/ Undisclosed"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Forge Biologics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Agreement","leadProduct":"RJVA-001","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forge Biologics \/ Forge Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Forge Biologics \/ Forge Biologics"},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"RJVA-001","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Fractyl Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fractyl Health \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Fractyl Health \/ Undisclosed"},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Nantahala Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Public Offering","leadProduct":"RJVA-001","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Fractyl Health","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Fractyl Health \/ Nantahala Capital","highestDevelopmentStatusID":"5","companyTruncated":"Fractyl Health \/ Nantahala Capital"},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Nantahala Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Public Offering","leadProduct":"RJVA-001","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Fractyl Health","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Fractyl Health \/ Nantahala Capital","highestDevelopmentStatusID":"5","companyTruncated":"Fractyl Health \/ Nantahala Capital"},{"orgOrder":0,"company":"Popular Medical College Hospital","sponsor":"Pi Research and Development Center | Incepta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BANGLADESH","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Popular Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Popular Medical College Hospital \/ Pi Research and Development Center | Incepta Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Popular Medical College Hospital \/ Pi Research and Development Center | Incepta Pharmaceuticals"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Merdury Pharmaceutical","sponsor":"Health2Sync","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Peptide, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Merdury Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merdury Pharmaceutical \/ Health2Sync","highestDevelopmentStatusID":"4","companyTruncated":"Merdury Pharmaceutical \/ Health2Sync"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Jiuyuan Gene Engineering","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Hangzhou Jiuyuan Gene Engineering","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hangzhou Jiuyuan Gene Engineering \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Jiuyuan Gene Engineering \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Medical Center Groningen \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"University Medical Center Groningen \/ Novo Nordisk"},{"orgOrder":0,"company":"St Andrew's Healthcare","sponsor":"Loughborough University","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"St Andrew's Healthcare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"St Andrew's Healthcare \/ Loughborough University","highestDevelopmentStatusID":"11","companyTruncated":"St Andrew's Healthcare \/ Loughborough University"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Loma Linda University","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Loma Linda University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loma Linda University \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Loma Linda University \/ Novo Nordisk"},{"orgOrder":0,"company":"Western University, Canada","sponsor":"London Health Sciences Centre Research Institute (Lawson) | Queen Elizabeth II Health Sciences Centre | St. Michael's Hospital (Toronto, Canada)","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Western University, Canada","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Western University, Canada \/ London Health Sciences Centre Research Institute (Lawson) | Queen Elizabeth II Health Sciences Centre | St. Michael's Hospital (Toronto, Canada)","highestDevelopmentStatusID":"11","companyTruncated":"Western University, Canada \/ London Health Sciences Centre Research Institute (Lawson) | Queen Elizabeth II Health Sciences Centre | St. Michael's Hospital (Toronto, Canada)"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Pennsylvania \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ Novo Nordisk"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Private Placement","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Vivani Medical","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Vivani Medical \/ Undisclosed"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Vivani Medical \/ Undisclosed"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Pill","sponsorNew":"Rani Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | Phenomix Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | Phenomix Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Mayo Clinic \/ National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | Phenomix Sciences"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mayo Clinic \/ Undisclosed"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Vivani Medical \/ Undisclosed"},{"orgOrder":0,"company":"Ali Aminian","sponsor":"Ethicon","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Ali Aminian","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ali Aminian \/ Ethicon","highestDevelopmentStatusID":"11","companyTruncated":"Ali Aminian \/ Ethicon"},{"orgOrder":0,"company":"Syntis Bio","sponsor":"Cerberus Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Series A Financing","leadProduct":"SYNT-101","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Syntis Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.040000000000000001,"dosageForm":"Pill","sponsorNew":"Syntis Bio \/ Cerberus Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Syntis Bio \/ Cerberus Ventures"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TERN-601","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terns Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TERN-601","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terns Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TERN-601","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terns Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Verdiva Bio","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"VRB-101","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Verdiva Bio","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.40999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Verdiva Bio \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Verdiva Bio \/ Forbion"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Sciwind Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"XW003","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sciwind Biosciences \/ Sciwind Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Sciwind Biosciences"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"XW003","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"XW003","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"XW014","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sciwind Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sciwind Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Oxyntomodulin","moa":"GLP-1 receptor\/Glucagon receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Olatorepatide","moa":"GLP-1\/GIP receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Hansoh Pharma","amount2":2.0099999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.0099999999999998,"dosageForm":"Injection","sponsorNew":"Hansoh Pharma \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Hansoh Pharma \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"HM15211","moa":"GLP-1\/GIP\/Glucagon receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"DR10624","moa":"GLP-1\/GCG\/FGF21 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang Doer Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Doer Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"DR10624","moa":"GLP-1\/GCG\/FGF21 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang Doer Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Doer Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"DR10624","moa":"GLP-1\/GCG\/FGF21 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang Doer Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Doer Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AMG133","moa":"GLP-1|GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"HS-20094","moa":"GLP-1\/GIP receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"HS-20094","moa":"GLP-1\/GIP receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"HS-20094","moa":"GLP-1|GIP receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"The United Laboratories","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"HONG KONG","productType":"Peptide, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"UBT251","moa":"GLP-1\/GIP\/Glucagon receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"The United Laboratories","amount2":2,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2,"dosageForm":"Injection","sponsorNew":"The United Laboratories \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"The United Laboratories \/ Novo Nordisk"},{"orgOrder":0,"company":"The United Bio-Technology (Hengqin) Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"UBT251","moa":"GLP-1|GIP|Glucagon receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"The United Bio-Technology (Hengqin) Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"The United Bio-Technology (Hengqin) Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The United Bio-Technology (Hengqin) Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lotiglipron","moa":"GLP1R||Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lotiglipron","moa":"GLP1R||Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Zealand Pharma"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Carnegie Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.20999999999999999,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Carnegie Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Carnegie Investment Bank"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Zealand Pharma"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Zealand Pharma"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CT-996","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CT-996","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"HM15136","moa":"GLP-1R\/GIPR\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HM15275","moa":"GLP-1R\/GIPR\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Gentofte, Copenhagen","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"University Hospital Gentofte, Copenhagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Gentofte, Copenhagen \/ Zealand Pharma","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Gentofte, Copenhagen \/ Zealand Pharma"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Goldman Sachs International","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0.90000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.90000000000000002,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Goldman Sachs International","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Goldman Sachs International"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Goldman Sachs International","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":1,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.90000000000000002,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Goldman Sachs International","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Goldman Sachs International"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Profil Institut f\u00fcr Stoffwechselforschung GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Profil Institut f\u00fcr Stoffwechselforschung GmbH"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Hormone","year":"2023","type":"Private Placement","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Danske Bank"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Danuglipron","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Danuglipron","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Danuglipron","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Danuglipron","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Danuglipron","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Danuglipron","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Danuglipron","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Danuglipron","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efpeglenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Efpeglenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Parexel"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Amylin Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of California, Los Angeles \/ Amylin Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"University of California, Los Angeles \/ Amylin Pharmaceuticals"},{"orgOrder":0,"company":"Children's Hospitals and Clinics of Minnesota","sponsor":"Amylin Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Children's Hospitals and Clinics of Minnesota","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospitals and Clinics of Minnesota \/ Amylin Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Children's Hospitals and Clinics of Minnesota \/ Amylin Pharmaceuticals"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Avance Clinical"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Undisclosed"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Undisclosed"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Undisclosed"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Undisclosed"},{"orgOrder":0,"company":"Jody Dushay","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Jody Dushay","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jody Dushay \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Jody Dushay \/ AstraZeneca"},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"Evira AB","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Karolinska Institutet","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karolinska Institutet \/ Evira AB","highestDevelopmentStatusID":"1","companyTruncated":"Karolinska Institutet \/ Evira AB"},{"orgOrder":0,"company":"University of Leicester","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Leicester","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Leicester \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"University of Leicester \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Emirates Health Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.A.E","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Emirates Health Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emirates Health Services \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Emirates Health Services \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Pennsylvania \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ Novo Nordisk"},{"orgOrder":0,"company":"Texas Tech University","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Texas Tech University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Texas Tech University \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Texas Tech University \/ Novo Nordisk"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"UT Southwestern Medical Center \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ Novo Nordisk"},{"orgOrder":0,"company":"Medix","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"MEXICO","productType":"Peptide, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Medix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medix \/ Biocon","highestDevelopmentStatusID":"15","companyTruncated":"Medix \/ Biocon"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Mayo Clinic \/ Novo Nordisk"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ National Institute of Diabetes and Digestive and Kidney Diseases | Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Mayo Clinic \/ National Institute of Diabetes and Digestive and Kidney Diseases | Novo Nordisk"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Novo Nordisk"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Michael Camilleri, MD","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Michael Camilleri, MD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Michael Camilleri, MD \/ National Institute of Diabetes and Digestive and Kidney Diseases | Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Michael Camilleri, MD \/ National Institute of Diabetes and Digestive and Kidney Diseases | Novo Nordisk"},{"orgOrder":0,"company":"PegBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PB-119","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"PegBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PegBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PegBio \/ Undisclosed"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RGT-075","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RGT-075","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Eli Lilly"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johns Hopkins University \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ Eli Lilly"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly | National Institute on Minority Health and Health Disparities","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Eli Lilly | National Institute on Minority Health and Health Disparities","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Eli Lilly | National Institute on Minority Health and Health Disparities"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"University of Melbourne","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Melbourne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Melbourne \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"University of Melbourne \/ Eli Lilly"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Cotadutide","moa":"Glucagon-like peptide 1 receptor | Glucagon receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"JNJ-64565111","moa":"Glucagon-like peptide 1 receptor | Glucagon receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"JNJ-64565111","moa":"Glucagon-like peptide 1 receptor | Glucagon receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"OPKO Biologics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Teduglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ OPKO Biologics","highestDevelopmentStatusID":"4","companyTruncated":"EnteraBio Ltd \/ OPKO Biologics"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Miricorilant","moa":"glucocorticoid receptor antagonists (not glucocorticoids)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Miricorilant","moa":"glucocorticoid receptor antagonists (not glucocorticoids)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Miricorilant","moa":"glucocorticoid receptor antagonists (not glucocorticoids)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Miricorilant","moa":"glucocorticoid receptor antagonists (not glucocorticoids)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Miricorilant","moa":"glucocorticoid receptor antagonists (not glucocorticoids)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ National Institute of Diabetes and Digestive and Kidney Diseases | Abbott Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clinic \/ National Institute of Diabetes and Digestive and Kidney Diseases | Abbott Laboratories"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"Growth factor receptor-bound protein 2 mRNA","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"Growth factor receptor-bound protein 2 mRNA","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"Growth factor receptor-bound protein 2 mRNA","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"Growth factor receptor-bound protein 2 mRNA","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"Growth factor receptor-bound protein 2 mRNA","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Growth Hormone","moa":"Growth hormone receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Massachusetts General Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"National Institutes of Health | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Growth Hormone","moa":"Growth hormone receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Massachusetts General Hospital \/ National Institutes of Health | Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ National Institutes of Health | Pfizer Inc"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Massachusetts General Hospital \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Genentech"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Janssen Ireland","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"CIN-109","moa":"Growth\/differentiation factor 15 (GDF15)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CinRx Pharma \/ Janssen Ireland","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Janssen Ireland"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"CIN-109","moa":"Growth\/differentiation factor 15 (GDF15)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.17999999999999999,"dosageForm":"Undisclosed","sponsorNew":"CinRx Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Undisclosed"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Undisclosed"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Undisclosed"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Trevogrumab","moa":"Growth\/differentiation factor 8","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aker BioMarine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NORWAY","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Bifidobacterium Lactis","moa":"||Gut microbiome","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Aker BioMarine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Aker BioMarine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aker BioMarine \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BERMUDA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"High Point Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"HPP404","moa":"H3R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"High Point Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"High Point Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"High Point Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HDM1005","moa":"HDM allergens","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HDM1005","moa":"HDM allergens","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HDM1005","moa":"HDM allergens","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Human Normal Immunoglobulin","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Universit\u00e9 de Montr\u00e9al","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Universit\u00e9 de Montr\u00e9al","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e9 de Montr\u00e9al \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Universit\u00e9 de Montr\u00e9al \/ Pfizer Inc"},{"orgOrder":0,"company":"AMIpharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Polyene Phosphatidylcholine","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AMIpharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMIpharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AMIpharm \/ Undisclosed"},{"orgOrder":0,"company":"AMIpharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Polyene Phosphatidylcholine","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AMIpharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"AMIpharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AMIpharm \/ Undisclosed"},{"orgOrder":0,"company":"AMIpharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Polyene Phosphatidylcholine","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AMIpharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMIpharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AMIpharm \/ Undisclosed"},{"orgOrder":0,"company":"Certmedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Polyglucosamine","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Certmedica","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Certmedica \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Certmedica \/ Undisclosed"},{"orgOrder":0,"company":"Heilpflanzenwohl","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Polyglucosamine Glucomannan","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Heilpflanzenwohl","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"Heilpflanzenwohl \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Heilpflanzenwohl \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Smofkabiven E","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Smoflipid","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Smoflipid","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ALN-4324","moa":"HSD17B13","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Green Cross Well-being","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BST204","moa":"IL-6 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Green Cross Well-being","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Cross Well-being \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Green Cross Well-being \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"China Medical University Hospital","sponsor":"TCI Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"China Medical University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China Medical University Hospital \/ TCI Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"China Medical University Hospital \/ TCI Co., Ltd."},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Glac Biotech Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Glac Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glac Biotech Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Glac Biotech Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Chung Shan Medical University","sponsor":"Grape King Bio Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Chung Shan Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chung Shan Medical University \/ Grape King Bio Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Chung Shan Medical University \/ Grape King Bio Ltd."},{"orgOrder":0,"company":"Chung Shan Medical University","sponsor":"Nutrarex Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Chung Shan Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chung Shan Medical University \/ Nutrarex Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Chung Shan Medical University \/ Nutrarex Biotech"},{"orgOrder":0,"company":"Bioithas SL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Bioithas SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bioithas SL \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bioithas SL \/ Undisclosed"},{"orgOrder":0,"company":"Probi AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Probiotic","year":"2016","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Probi AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Probi AB \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Probi AB \/ Undisclosed"},{"orgOrder":0,"company":"Biopolis S.L.","sponsor":"Technological Centre of Nutrition and Health | Hospital Universitari Sant Joan de Reus | University Rovira i Virgili","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Probiotic","year":"2016","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Biopolis S.L.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biopolis S.L. \/ Technological Centre of Nutrition and Health | Hospital Universitari Sant Joan de Reus | University Rovira i Virgili","highestDevelopmentStatusID":"10","companyTruncated":"Biopolis S.L. \/ Technological Centre of Nutrition and Health | Hospital Universitari Sant Joan de Reus | University Rovira i Virgili"},{"orgOrder":0,"company":"University of Manitoba","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Probiotic","year":"2016","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Manitoba \/ Lallemand Health Solutions","highestDevelopmentStatusID":"1","companyTruncated":"University of Manitoba \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"Hospital General de Mexico","sponsor":"Italmex Pharma | Medix Farma | National Polytechnic Institute, Mexico","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"MEXICO","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Hospital General de Mexico","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital General de Mexico \/ Italmex Pharma | Medix Farma | National Polytechnic Institute, Mexico","highestDevelopmentStatusID":"1","companyTruncated":"Hospital General de Mexico \/ Italmex Pharma | Medix Farma | National Polytechnic Institute, Mexico"},{"orgOrder":0,"company":"Biowish Technologies, Inc.","sponsor":"University of Wollongong | Mysore Medical College and Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Biowish Technologies, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biowish Technologies, Inc. \/ University of Wollongong | Mysore Medical College and Research Institute","highestDevelopmentStatusID":"1","companyTruncated":"Biowish Technologies, Inc. \/ University of Wollongong | Mysore Medical College and Research Institute"},{"orgOrder":0,"company":"Prisma Health-Upstate","sponsor":"Xymogen, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Prisma Health-Upstate","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prisma Health-Upstate \/ Xymogen, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Prisma Health-Upstate \/ Xymogen, Inc."},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"Centre de recherche en nutrition humaine de Rh\u00f4ne-Alpes","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ Centre de recherche en nutrition humaine de Rh\u00f4ne-Alpes","highestDevelopmentStatusID":"8","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ Centre de recherche en nutrition humaine de Rh\u00f4ne-Alpes"},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Archer Daniels Midland \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Undisclosed"},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Nois de M\u00e9xico","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Archer Daniels Midland \/ Nois de M\u00e9xico","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Nois de M\u00e9xico"},{"orgOrder":0,"company":"Rosa Sola","sponsor":"Biopolis S.L. | Chic-kles Gum, S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Rosa Sola","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Gum, Chewing","sponsorNew":"Rosa Sola \/ Biopolis S.L. | Chic-kles Gum, S.L.","highestDevelopmentStatusID":"1","companyTruncated":"Rosa Sola \/ Biopolis S.L. | Chic-kles Gum, S.L."},{"orgOrder":0,"company":"Helsinki University Central Hospital","sponsor":"Turku University Hospital | Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FINLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Whole Body Cryotherapy","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Helsinki University Central Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinki University Central Hospital \/ Turku University Hospital | Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Helsinki University Central Hospital \/ Turku University Hospital | Novo Nordisk"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"WVE-007","moa":"INHBE","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wave Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Wave Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-007","moa":"INHBE","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wave Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Wave Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"WVE-007","moa":"INHBE","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wave Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Wave Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Garetosmab","moa":"Inhibin beta A chain","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Technological Centre of Nutrition and Health, Spain","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Inulin","moa":"Insulin (INS)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Technological Centre of Nutrition and Health, Spain","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Technological Centre of Nutrition and Health, Spain \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Technological Centre of Nutrition and Health, Spain \/ Undisclosed"},{"orgOrder":0,"company":"Modular Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Modular Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modular Medical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Modular Medical \/ Undisclosed"},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Human Insulin","moa":"Insulin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Elgan Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Powder","sponsorNew":"Elgan Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Elgan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2023","type":"Funding","leadProduct":"Recombinant Human Insulin","moa":"Insulin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Elgan Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Powder","sponsorNew":"Elgan Pharma \/ European Innovation Council","highestDevelopmentStatusID":"10","companyTruncated":"Elgan Pharma \/ European Innovation Council"},{"orgOrder":0,"company":"CHRISTUS Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ferrous Sulfate","moa":"Iron stores","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"CHRISTUS Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CHRISTUS Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"CHRISTUS Health \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Biotin","moa":"||Krebs cycle activatior","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Nestle Health Sciences SA \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Children's Discovery Institute | Polaris Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Children's Discovery Institute | Polaris Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Children's Discovery Institute | Polaris Pharmaceuticals"},{"orgOrder":0,"company":"NuSirt Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Amino Acid","year":"2017","type":"Inapplicable","leadProduct":"L-Leucine","moa":"Leucine--tRNA ligase, mitochondrial; tRNA wybutosine-synthesizing protein 4; Leucine carboxyl methyltransferase 1; Leucine--tRNA ligase, cytoplasmic; Branched-chain-amino-acid aminotransferase, mitochondrial; Branched-chain-amino-acid aminotransferase, cytosolic","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"NuSirt Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NuSirt Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NuSirt Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Empros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Carbohydrate","year":"2025","type":"Inapplicable","leadProduct":"Acarbose","moa":"LIPF|MGAM","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Empros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Empros Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Empros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Spaulding Clinical, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Spaulding Clinical, LLC"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Raziel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raziel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"365mc","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ 365mc","highestDevelopmentStatusID":"10","companyTruncated":"Raziel Therapeutics \/ 365mc"},{"orgOrder":0,"company":"Fauqu\u00e9","sponsor":"Institut Polyclinique de Cannes (IPOCA)","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alpha Lipoic Acid","moa":"Lipoyl amidotransferase LIPT1, mitochondrial; Sodium-dependent multivitamin transporter; Lipoyl synthase, mitochondrial","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Fauqu\u00e9","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fauqu\u00e9 \/ Institut Polyclinique de Cannes (IPOCA)","highestDevelopmentStatusID":"1","companyTruncated":"Fauqu\u00e9 \/ Institut Polyclinique de Cannes (IPOCA)"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"ATLAS PHARMS LLC","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ ATLAS PHARMS LLC","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ ATLAS PHARMS LLC"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mifomelatide","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endevica Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Undisclosed"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endevica Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Undisclosed"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endevica Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Undisclosed"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endevica Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Undisclosed"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endevica Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Undisclosed"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endevica Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Undisclosed"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endevica Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Undisclosed"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endevica Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Undisclosed"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endevica Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Bivamelagon","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"LG Chem","amount2":0.31,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.31,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bivamelagon","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Congruence","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"CGX-926","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Congruence","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Congruence \/ Amplitude Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Congruence \/ Amplitude Ventures"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LB54640","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LB54640","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PL7737","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PL7737","moa":"||MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Alliance Global Partners"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RareStone Group","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Termination","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"RareStone Group","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"RareStone Group \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"RareStone Group \/ Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Genpharm","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Genpharm"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rhythm Pharmaceuticals \/ National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PF-07258669","moa":"Melanocortin receptor 4 (MC4R)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Zafgen, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Beloranib","moa":"Methionine aminopeptidase 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zafgen, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zafgen, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zafgen, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Zafgen, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Beloranib","moa":"Methionine aminopeptidase 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zafgen, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Zafgen, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zafgen, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Zafgen, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Beloranib","moa":"Methionine aminopeptidase 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zafgen, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Zafgen, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zafgen, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Zafgen, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Beloranib","moa":"Methionine aminopeptidase 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zafgen, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zafgen, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zafgen, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Zafgen, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Beloranib","moa":"Methionine aminopeptidase 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zafgen, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zafgen, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zafgen, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Zafgen, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Beloranib","moa":"Methionine aminopeptidase 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zafgen, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zafgen, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zafgen, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Centre For International Health","sponsor":"Tribhuvan University, Nepal | NORCE Norwegian Research Centre AS","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Vitamin B12","moa":"Methionine synthase; Methylmalonyl-CoA mutase, mitochondrial; Methionine synthase reductase; Methylmalonic aciduria type A protein, mitochondrial; Cyanocobalamin reductase \/ alkylcobalamin dealkylase; Methylenetetrahydrofolate reductase (NADPH)","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Centre For International Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Paste","sponsorNew":"Centre For International Health \/ Tribhuvan University, Nepal | NORCE Norwegian Research Centre AS","highestDevelopmentStatusID":"9","companyTruncated":"Centre For International Health \/ Tribhuvan University, Nepal | NORCE Norwegian Research Centre AS"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Staten Island University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Vitamin B12","moa":"Methionine synthase; Methylmalonyl-CoA mutase, mitochondrial; Methionine synthase reductase; Methylmalonic aciduria type A protein, mitochondrial; Cyanocobalamin reductase \/ alkylcobalamin dealkylase; Methylenetetrahydrofolate reductase (NADPH)","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Serum","sponsorNew":"Northwell Health \/ Staten Island University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Northwell Health \/ Staten Island University Hospital"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BMS-963272","moa":"MGAT2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"R256918","moa":"microsomal triglyceride transfer protein (MTP) inhibitors","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Silanes","sponsor":"INTEC Instituto de Terap\u00e9utica Experimental y Cl\u00ednica, Departamento de Fisiolog\u00eda, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara. | OAXACA SITE MANAGEMENT ORGANIZATION, SC | IBIOMED INVESTIGACI\u00d3N BIOM\u00c9DICA PARA EL DESARROLLO DE ","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"MEXICO","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial glycerol-3-phosphate dehydrogenase","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Laboratorios Silanes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Silanes \/ INTEC Instituto de Terap\u00e9utica Experimental y Cl\u00ednica, Departamento de Fisiolog\u00eda, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara. | OAXACA SITE MANAGEMENT ORGANIZATION, SC | IBIOMED INVESTIGACI\u00d3N BIOM\u00c9DICA PARA EL DESARROLLO DE ","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Silanes \/ INTEC Instituto de Terap\u00e9utica Experimental y Cl\u00ednica, Departamento de Fisiolog\u00eda, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara. | OAXACA SITE MANAGEMENT ORGANIZATION, SC | IBIOMED INVESTIGACI\u00d3N BIOM\u00c9DICA PARA EL DESARROLLO DE "},{"orgOrder":0,"company":"Biocinese","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Biocinese","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biocinese \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Biocinese \/ Undisclosed"},{"orgOrder":0,"company":"Metabolic Research Unit","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Metabolic Research Unit","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metabolic Research Unit \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Metabolic Research Unit \/ Undisclosed"},{"orgOrder":0,"company":"Promomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Promomed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Promomed \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Promomed \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sibutramine Hydrochloride","moa":"Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"New York State Psychiatric Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sibutramine Hydrochloride","moa":"Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"New York State Psychiatric Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New York State Psychiatric Institute \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"New York State Psychiatric Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BRAZIL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sibutramine Hydrochloride","moa":"Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Saniona","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Undisclosed"},{"orgOrder":0,"company":"Saniona","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Undisclosed"},{"orgOrder":0,"company":"Saniona","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Undisclosed"},{"orgOrder":0,"company":"Saniona","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Undisclosed"},{"orgOrder":0,"company":"Saniona","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Undisclosed"},{"orgOrder":0,"company":"Saniona","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Undisclosed"},{"orgOrder":0,"company":"Saniona","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Undisclosed"},{"orgOrder":0,"company":"Saniona","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"PF-06946860","moa":"monoclonal antibodies: mouse","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"AstralBio","sponsor":"iBio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"IBIO-600","moa":"MSTN","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"AstralBio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"AstralBio \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"AstralBio \/ iBio"},{"orgOrder":0,"company":"Veos Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"ThymoTropin","moa":"MSTN","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Veos Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veos Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Veos Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RDX-002","moa":"MTP","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Response Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Response Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RDX-002","moa":"MTP","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Response Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Response Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RDX-002","moa":"MTP","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Response Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Response Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RDX-002","moa":"MTP","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Response Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Response Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RDX-002","moa":"MTP","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Response Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Response Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"GSK1521498","moa":"Mu opioid receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Semmelweis University","sponsor":"Novonex Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"HUNGARY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Mucous clearance","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Semmelweis University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Semmelweis University \/ Novonex Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Semmelweis University \/ Novonex Pharma"},{"orgOrder":0,"company":"Ziekenhuis Oost-Limburg","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BELGIUM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"Muscle-type nicotinic acetylcholine receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Ziekenhuis Oost-Limburg","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ziekenhuis Oost-Limburg \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Ziekenhuis Oost-Limburg \/ Merck & Co"},{"orgOrder":0,"company":"University of Missouri-Columbia","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"Muscle-type nicotinic acetylcholine receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Missouri-Columbia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Missouri-Columbia \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Missouri-Columbia \/ Merck & Co"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"KER-065","moa":"Myostatin\/Activin A","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Choline Chloride","moa":"nACh-alpha-7 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Protara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Choline Chloride","moa":"nACh-alpha-7 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Protara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Protara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Choline Chloride","moa":"nACh-alpha-7 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Protara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Niagen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Niagen Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Niagen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Niagen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Niagen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Niagen Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Niagen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Niagen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Niagen Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sinopharm \/ ChromaDex, Inc","highestDevelopmentStatusID":"15","companyTruncated":"Sinopharm \/ ChromaDex, Inc"},{"orgOrder":0,"company":"Manjunath Prakash Pai","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oseltamivir Phosphate","moa":"Neuraminidase","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Manjunath Prakash Pai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Manjunath Prakash Pai \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Manjunath Prakash Pai \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CIN-110","moa":"Neuropeptide Y receptor type 2 (NPY2R)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"CinRx Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CIN-110","moa":"Neuropeptide Y receptor type 2 (NPY2R)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"CinRx Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Velneperit","moa":"Neuropeptide Y receptor type 5","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"pH Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"PHP-303","moa":"Neutrophil elastase","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"pH Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pH Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"pH Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Gelesis","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Citric Acid","moa":"||NGLY1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Gelesis","highestDevelopmentStatusID":"15","companyTruncated":"PureTech Health \/ Gelesis"},{"orgOrder":0,"company":"Gelesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Citric Acid","moa":"||NGLY1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Gelesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gelesis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gelesis \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Zomagen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VTX3232","moa":"NLRP3","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zomagen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zomagen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zomagen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"||NLRP3","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Ventyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ousia Pharma","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide-drug Conjugate","year":"2025","type":"Financing","leadProduct":"OP-175","moa":"NMDA receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Ousia Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ousia Pharma \/ Omega Funds","highestDevelopmentStatusID":"4","companyTruncated":"Ousia Pharma \/ Omega Funds"},{"orgOrder":0,"company":"Michelle Cardel, PhD, MS, RD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Michelle Cardel, PhD, MS, RD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Michelle Cardel, PhD, MS, RD \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Michelle Cardel, PhD, MS, RD \/ Undisclosed"},{"orgOrder":0,"company":"Novo Integrated Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Iodine","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Integrated Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Spray","sponsorNew":"Novo Integrated Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Integrated Sciences \/ Undisclosed"},{"orgOrder":0,"company":"AdventHealth Translational Research Institute","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Phentermine","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"AdventHealth Translational Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AdventHealth Translational Research Institute \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"AdventHealth Translational Research Institute \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"New York State Psychiatric Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Phentermine","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"New York State Psychiatric Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New York State Psychiatric Institute \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"New York State Psychiatric Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Vivus","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Phentermine","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Forest University Health Sciences \/ Vivus","highestDevelopmentStatusID":"8","companyTruncated":"Wake Forest University Health Sciences \/ Vivus"},{"orgOrder":0,"company":"Vivus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Phentermine","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Vivus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Undisclosed"},{"orgOrder":0,"company":"Alvogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phentermine","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Alvogen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Alvogen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alvogen \/ Undisclosed"},{"orgOrder":0,"company":"Vivus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Phentermine","moa":"||Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Vivus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Undisclosed"},{"orgOrder":0,"company":"Vivus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Phentermine","moa":"||Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Vivus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Undisclosed"},{"orgOrder":0,"company":"Vivus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Phentermine","moa":"||Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Vivus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Undisclosed"},{"orgOrder":0,"company":"Vivus","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Phentermine","moa":"||Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Vivus \/ Mayo Clinic","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Mayo Clinic"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Johns Hopkins University | Kaiser Permanente | HealthPartners Institute | University of Texas Health Science Center at Houston | Biomedical Research Institute of New Mexico | WW International Inc | KVK.Tech | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phentermine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Forest University Health Sciences \/ Johns Hopkins University | Kaiser Permanente | HealthPartners Institute | University of Texas Health Science Center at Houston | Biomedical Research Institute of New Mexico | WW International Inc | KVK.Tech | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"11","companyTruncated":"Wake Forest University Health Sciences \/ Johns Hopkins University | Kaiser Permanente | HealthPartners Institute | University of Texas Health Science Center at Houston | Biomedical Research Institute of New Mexico | WW International Inc | KVK.Tech | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"KVK.Tech","sponsor":"Medix","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"Phentermine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"KVK.Tech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KVK.Tech \/ Medix","highestDevelopmentStatusID":"15","companyTruncated":"KVK.Tech \/ Medix"},{"orgOrder":0,"company":"The Royal's Institute of Mental Health Research","sponsor":"University of Ottawa | The Royal Ottawa Mental Health Centre | Bausch Health | CHEO Research Institute | LEAF Weight Management Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"The Royal's Institute of Mental Health Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Royal's Institute of Mental Health Research \/ University of Ottawa | The Royal Ottawa Mental Health Centre | Bausch Health | CHEO Research Institute | LEAF Weight Management Clinic","highestDevelopmentStatusID":"11","companyTruncated":"The Royal's Institute of Mental Health Research \/ University of Ottawa | The Royal Ottawa Mental Health Centre | Bausch Health | CHEO Research Institute | LEAF Weight Management Clinic"},{"orgOrder":0,"company":"Kintampo Health Research Centre, Ghana","sponsor":"University of Wisconsin, Madison","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GHANA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Vitamin A","moa":"NR1B","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Kintampo Health Research Centre, Ghana","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintampo Health Research Centre, Ghana \/ University of Wisconsin, Madison","highestDevelopmentStatusID":"1","companyTruncated":"Kintampo Health Research Centre, Ghana \/ University of Wisconsin, Madison"},{"orgOrder":0,"company":"London School of Hygiene & Tropical Medicine","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Vitamin A","moa":"NR1B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"London School of Hygiene & Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London School of Hygiene & Tropical Medicine \/ World Health Organization","highestDevelopmentStatusID":"8","companyTruncated":"London School of Hygiene & Tropical Medicine \/ World Health Organization"},{"orgOrder":0,"company":"Kallyope","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"K-757","moa":"Nutrient receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kallyope \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kallyope \/ Undisclosed"},{"orgOrder":0,"company":"Kallyope","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"K-757","moa":"Nutrient receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kallyope \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kallyope \/ Undisclosed"},{"orgOrder":0,"company":"Kallyope","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"K-757","moa":"Nutrient receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kallyope \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kallyope \/ Undisclosed"},{"orgOrder":0,"company":"Kallyope","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"K-757","moa":"Nutrient receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kallyope \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kallyope \/ Undisclosed"},{"orgOrder":0,"company":"Kallyope","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"K-757","moa":"||Nutrient receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kallyope \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kallyope \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Orexigen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Orexigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orexigen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Orexigen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Currax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"||Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Currax","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Currax \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Currax \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"University of Massachusetts, Worcester","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Mental Health Center \/ University of Massachusetts, Worcester","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Mental Health Center \/ University of Massachusetts, Worcester"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Orexigen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NORWAY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ Orexigen Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Oslo University Hospital \/ Orexigen Therapeutics"},{"orgOrder":0,"company":"Orexigen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Orexigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orexigen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orexigen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Bausch Health","highestDevelopmentStatusID":"11","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Bausch Health"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Bausch Health","highestDevelopmentStatusID":"11","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Bausch Health"},{"orgOrder":0,"company":"Laval University","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laval University \/ Bausch Health","highestDevelopmentStatusID":"11","companyTruncated":"Laval University \/ Bausch Health"},{"orgOrder":0,"company":"Currax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Currax","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Currax \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Currax \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Magnesium","moa":"||Oxytocin receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Yale-NUS College","sponsor":"Singapore General Hospital | SingHealth Investigational Medicine Unit","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SINGAPORE","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Yale-NUS College","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale-NUS College \/ Singapore General Hospital | SingHealth Investigational Medicine Unit","highestDevelopmentStatusID":"8","companyTruncated":"Yale-NUS College \/ Singapore General Hospital | SingHealth Investigational Medicine Unit"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Empros Pharma","sponsor":"CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Empros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Prolonged Release","sponsorNew":"Empros Pharma \/ CTC Clinical Trial Consultants","highestDevelopmentStatusID":"8","companyTruncated":"Empros Pharma \/ CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"Empros Pharma","sponsor":"CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Empros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Prolonged Release","sponsorNew":"Empros Pharma \/ CTC Clinical Trial Consultants","highestDevelopmentStatusID":"8","companyTruncated":"Empros Pharma \/ CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Hamell","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Hamell","highestDevelopmentStatusID":"1","companyTruncated":"GSK \/ Hamell"},{"orgOrder":0,"company":"Mid-Atlantic Epilepsy and Sleep Center, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Mid-Atlantic Epilepsy and Sleep Center, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mid-Atlantic Epilepsy and Sleep Center, LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mid-Atlantic Epilepsy and Sleep Center, LLC \/ Undisclosed"},{"orgOrder":0,"company":"University of Campinas, Brazil","sponsor":"Germed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Campinas, Brazil","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Campinas, Brazil \/ Germed","highestDevelopmentStatusID":"1","companyTruncated":"University of Campinas, Brazil \/ Germed"},{"orgOrder":0,"company":"University of Campinas, Brazil","sponsor":"Germed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BRAZIL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Campinas, Brazil","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Campinas, Brazil \/ Germed","highestDevelopmentStatusID":"1","companyTruncated":"University of Campinas, Brazil \/ Germed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Certmedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Certmedica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Certmedica \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Certmedica \/ Undisclosed"},{"orgOrder":0,"company":"Empros Pharma","sponsor":"CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Empros Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Empros Pharma \/ CTC Clinical Trial Consultants","highestDevelopmentStatusID":"6","companyTruncated":"Empros Pharma \/ CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"Anglo-French Drugs and industries","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Nicotinamide","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Anglo-French Drugs and industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anglo-French Drugs and industries \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Anglo-French Drugs and industries \/ Lupin Ltd"},{"orgOrder":0,"company":"Clinical Nutrition Research Center, Illinois Institute of Technology","sponsor":"Food and Drug Administration","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Mango","moa":"PDE5A","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Clinical Nutrition Research Center, Illinois Institute of Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ Food and Drug Administration","highestDevelopmentStatusID":"1","companyTruncated":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ Food and Drug Administration"},{"orgOrder":0,"company":"Gubra","sponsor":"Skandinaviska Enskilda Banken","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Amylin","moa":"peptides: amylin derivatives or mimics","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Gubra","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Gubra \/ Skandinaviska Enskilda Banken","highestDevelopmentStatusID":"4","companyTruncated":"Gubra \/ Skandinaviska Enskilda Banken"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pioglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bardoxolone Methyl","moa":"Peroxisome proliferator-activated receptor gamma | Keap1\/Nrf2 | Inhibitor of nuclear factor kappa B kinase beta subunit","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Torrent Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Calcium","moa":"||Phosphate","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Torrent Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Powder","sponsorNew":"Torrent Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Torrent Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Instituto Palacios","sponsor":"Nexentia S.A.S.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Calcium","moa":"Phosphate","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Instituto Palacios","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto Palacios \/ Nexentia S.A.S.","highestDevelopmentStatusID":"10","companyTruncated":"Instituto Palacios \/ Nexentia S.A.S."},{"orgOrder":0,"company":"Neothetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"LIPO-102","moa":"Phosphodiesterase","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Neothetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neothetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neothetics \/ Undisclosed"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Soleno Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Soleno Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Soleno Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.20000000000000001,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Soleno Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Soleno Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.20000000000000001,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Soleno Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Diazoxide","moa":"ABCC8(SUR1)\/KCNJ11(KIR6.2)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Soleno Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Soleno Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Northumbria University","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Northumbria University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northumbria University \/ PRONOVA BIOPHARMA NORGE AS","highestDevelopmentStatusID":"1","companyTruncated":"Northumbria University \/ PRONOVA BIOPHARMA NORGE AS"},{"orgOrder":0,"company":"McMaster University","sponsor":"Neptune","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oil","sponsorNew":"McMaster University \/ Neptune","highestDevelopmentStatusID":"1","companyTruncated":"McMaster University \/ Neptune"},{"orgOrder":0,"company":"Aristotle University Of Thessaloniki","sponsor":"NattoPharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GREECE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Menaquinone-7","moa":"Pregnane X receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Aristotle University Of Thessaloniki","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aristotle University Of Thessaloniki \/ NattoPharma","highestDevelopmentStatusID":"1","companyTruncated":"Aristotle University Of Thessaloniki \/ NattoPharma"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Megestrol Acetate","moa":"Progesterone receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Saskatchewan Health Authority \u2013 Regina Area","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dinoprostone","moa":"Prostaglandin E2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Saskatchewan Health Authority \u2013 Regina Area","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saskatchewan Health Authority \u2013 Regina Area \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Saskatchewan Health Authority \u2013 Regina Area \/ Undisclosed"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Nutricia","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Protein","moa":"Protein","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charite University, Berlin, Germany \/ Nutricia","highestDevelopmentStatusID":"1","companyTruncated":"Charite University, Berlin, Germany \/ Nutricia"},{"orgOrder":0,"company":"Hospital Clinic of Barcelona","sponsor":"Garmin International | Institut Nacional d'Educacio Fisica de Catalunya","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Protein","moa":"Protein","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Hospital Clinic of Barcelona","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Clinic of Barcelona \/ Garmin International | Institut Nacional d'Educacio Fisica de Catalunya","highestDevelopmentStatusID":"1","companyTruncated":"Hospital Clinic of Barcelona \/ Garmin International | Institut Nacional d'Educacio Fisica de Catalunya"},{"orgOrder":0,"company":"University of Calgary","sponsor":"General Mills","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Protein","moa":"Protein","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ General Mills","highestDevelopmentStatusID":"1","companyTruncated":"University of Calgary \/ General Mills"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Protein","moa":"Protein","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ National Institute on Aging","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ National Institute on Aging"},{"orgOrder":0,"company":"Metabolics Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ENT-03","moa":"PTP1B","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Metabolics Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metabolics Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Metabolics Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Graviton Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GV101","moa":"ROCK2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Graviton Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Graviton Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Graviton Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Lipidio Pharmaceuticals","sponsor":"Maxim Merchant Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series A Financing","leadProduct":"GDD3898","moa":"SCD1","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipidio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipidio Pharmaceuticals \/ Maxim Merchant Capital","highestDevelopmentStatusID":"8","companyTruncated":"Lipidio Pharmaceuticals \/ Maxim Merchant Capital"},{"orgOrder":0,"company":"Short Wave Pharma","sponsor":"The Sheba Center for Eating Disorders","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Short Wave Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Short Wave Pharma \/ The Sheba Center for Eating Disorders","highestDevelopmentStatusID":"7","companyTruncated":"Short Wave Pharma \/ The Sheba Center for Eating Disorders"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kindred Biosciences","sponsor":"Dechra Pharmaceuticals Manufacturing","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Divestment","leadProduct":"Mirtazapine","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor | Adrenergic receptor alpha-2","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Kindred Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Kindred Biosciences \/ Dechra Pharmaceuticals Manufacturing","highestDevelopmentStatusID":"15","companyTruncated":"Kindred Biosciences \/ Dechra Pharmaceuticals Manufacturing"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lorcaserin HCl","moa":"Serotonin 2c (5-HT2c) receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Eisai Inc","highestDevelopmentStatusID":"1","companyTruncated":"University of Pennsylvania \/ Eisai Inc"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lorcaserin HCl","moa":"Serotonin 2c (5-HT2c) receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Kanion & Huawe Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lorcaserin HCl","moa":"Serotonin 2c (5-HT2c) receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Kanion & Huawe Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kanion & Huawe Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kanion & Huawe Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lorcaserin HCl","moa":"Serotonin 2c (5-HT2c) receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lorcaserin HCl","moa":"Serotonin 2c (5-HT2c) receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Theracos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Theracos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theracos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theracos \/ Undisclosed"},{"orgOrder":0,"company":"Vivus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"VI-0521","moa":"SGLT1\/SGLT2","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vivus \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Vivus \/ Undisclosed"},{"orgOrder":0,"company":"Vivus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"VI-0521","moa":"SGLT1\/SGLT2","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vivus \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Vivus \/ Undisclosed"},{"orgOrder":0,"company":"Universit\u00e4tsklinikum Hamburg-Eppendorf","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Universit\u00e4tsklinikum Hamburg-Eppendorf","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Universit\u00e4tsklinikum Hamburg-Eppendorf \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Universit\u00e4tsklinikum Hamburg-Eppendorf \/ AstraZeneca"},{"orgOrder":0,"company":"Uppsala University","sponsor":"Uppsala University Hospital | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Uppsala University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uppsala University \/ Uppsala University Hospital | AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Uppsala University \/ Uppsala University Hospital | AstraZeneca"},{"orgOrder":0,"company":"Christopher Bell","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Christopher Bell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Christopher Bell \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Christopher Bell \/ AstraZeneca"},{"orgOrder":0,"company":"Christopher Bell","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Christopher Bell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Christopher Bell \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Christopher Bell \/ AstraZeneca"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Pharmaceutical Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Pharmaceutical Research Institute","highestDevelopmentStatusID":"11","companyTruncated":"University of Copenhagen \/ Pharmaceutical Research Institute"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"LIK066","moa":"Sodium\/glucose cotransporter 1 | Sodium\/glucose cotransporter 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"LIK066","moa":"Sodium\/glucose cotransporter 1 | Sodium\/glucose cotransporter 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"LIK066","moa":"Sodium\/glucose cotransporter 1 | Sodium\/glucose cotransporter 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"LIK066","moa":"Sodium\/glucose cotransporter 1 | Sodium\/glucose cotransporter 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"HPAPI","year":"2014","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mario Negri Institute for Pharmacological Research","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Mario Negri Institute for Pharmacological Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mario Negri Institute for Pharmacological Research \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Mario Negri Institute for Pharmacological Research \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Potassium Chloride","moa":"Solute carrier family 12 member 1 (SLC12A1)","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rivus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series B Financing","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Rivus Pharmaceuticals \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ RA Capital Management"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Repaglinide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Foralumab","moa":"||T cell surface glycoprotein CD3","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiziana Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"University of California, San Diego","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aardvark Therapeutics \/ University of California, San Diego","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ University of California, San Diego"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"University of California, San Diego","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aardvark Therapeutics \/ University of California, San Diego","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ University of California, San Diego"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aardvark Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aardvark Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Aardvark Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Aardvark Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Aardvark Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sirnaomics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Undisclosed"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sirnaomics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Undisclosed"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP705","moa":"TGF-beta-1\/COX-2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Eastern Mennonite Missions | Arup Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Vitamin B1","moa":"Thiamine pyrophosphokinase 1; Pyruvate dehydrogenase E1 component","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Eastern Mennonite Missions | Arup Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clinic \/ Eastern Mennonite Missions | Arup Laboratories"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ASC41","moa":"THR-?","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Gannex Pharma","sponsor":"Hunan Provincial People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ASC41","moa":"THR-?","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gannex Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gannex Pharma \/ Hunan Provincial People's Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Gannex Pharma \/ Hunan Provincial People's Hospital"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ASC47","moa":"THR-?","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ASC47","moa":"THR-?","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ASC47","moa":"THR-?","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ASC47","moa":"||THR-?","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ASC47","moa":"||THR-\u03b2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ASC31","moa":"||THR-\u03b2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"P7435","moa":"TLR8","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Piramal Enterprises Limited \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Enterprises Limited \/ Undisclosed"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TNF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Palmitoylethanolamide","moa":"||TNF-alpha receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"1","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Action Contre la Faim | Centre de Recherches M\u00e9dicales et Sanitaires CERMES Niger | Institut Pasteur de Madagascar | Institut Pasteur de Bangui | Institut Pasteur de Dakar","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Albendazole","moa":"Tubulin","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Pasteur \/ Action Contre la Faim | Centre de Recherches M\u00e9dicales et Sanitaires CERMES Niger | Institut Pasteur de Madagascar | Institut Pasteur de Bangui | Institut Pasteur de Dakar","highestDevelopmentStatusID":"10","companyTruncated":"Institut Pasteur \/ Action Contre la Faim | Centre de Recherches M\u00e9dicales et Sanitaires CERMES Niger | Institut Pasteur de Madagascar | Institut Pasteur de Bangui | Institut Pasteur de Dakar"},{"orgOrder":0,"company":"McGill University Health Centre Research Institute","sponsor":"McGill University | Asociacion Civil Selva Amazonica | World Health Organization | Thrasher Research Fund | Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Mebendazole","moa":"Tubulin","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"McGill University Health Centre Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"McGill University Health Centre Research Institute \/ McGill University | Asociacion Civil Selva Amazonica | World Health Organization | Thrasher Research Fund | Canadian Institutes of Health Research","highestDevelopmentStatusID":"11","companyTruncated":"McGill University Health Centre Research Institute \/ McGill University | Asociacion Civil Selva Amazonica | World Health Organization | Thrasher Research Fund | Canadian Institutes of Health Research"},{"orgOrder":0,"company":"ProGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"PG-102","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"ProGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProGen \/ Undisclosed"},{"orgOrder":0,"company":"Kantonsspital Aarau","sponsor":"Clinical Trial Unit, University Hospital Basel | University Hospital, Basel | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Kantonsspital Aarau","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kantonsspital Aarau \/ Clinical Trial Unit, University Hospital Basel | University Hospital, Basel | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Kantonsspital Aarau \/ Clinical Trial Unit, University Hospital Basel | University Hospital, Basel | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Laboratorios Silanes","sponsor":"Hospital General de Mexico","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"MEXICO","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Conjugated Linoleic Acid","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Laboratorios Silanes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laboratorios Silanes \/ Hospital General de Mexico","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Silanes \/ Hospital General de Mexico"},{"orgOrder":0,"company":"Smartfish","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NORWAY","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Nutrifriend Cachexia","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Smartfish","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Smartfish \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Smartfish \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Metagenics | North Carolina Translational and Clinical Sciences Institute","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"SPM Active","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of North Carolina \/ Metagenics | North Carolina Translational and Clinical Sciences Institute","highestDevelopmentStatusID":"1","companyTruncated":"University of North Carolina \/ Metagenics | North Carolina Translational and Clinical Sciences Institute"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"METAGENICS","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"SPM Active","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of North Carolina \/ Metagenics","highestDevelopmentStatusID":"1","companyTruncated":"University of North Carolina \/ Metagenics"},{"orgOrder":0,"company":"Vedic Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Citrus Flavonone-O-Glycosides","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Vedic Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedic Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vedic Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Advanced Protein Technologies Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Carbohydrate","year":"2024","type":"Inapplicable","leadProduct":"2-fucosyllactose","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Advanced Protein Technologies Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advanced Protein Technologies Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Advanced Protein Technologies Corporation \/ Undisclosed"},{"orgOrder":0,"company":"KGK Science","sponsor":"InterHealth Nutraceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"7-Keto","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ InterHealth Nutraceuticals, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ InterHealth Nutraceuticals, Inc."},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"A07D","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endevica Bio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Endevica Bio \/ Undisclosed"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ACCG-2671","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Structure Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plexus Worldwide","sponsor":"George Mason University","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Aframomum Melegueta","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Plexus Worldwide","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plexus Worldwide \/ George Mason University","highestDevelopmentStatusID":"1","companyTruncated":"Plexus Worldwide \/ George Mason University"},{"orgOrder":0,"company":"Fondazione Edmund Mach","sponsor":"Cargill | Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Aleurone","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Fondazione Edmund Mach","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fondazione Edmund Mach \/ Cargill | Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento","highestDevelopmentStatusID":"1","companyTruncated":"Fondazione Edmund Mach \/ Cargill | Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento"},{"orgOrder":0,"company":"Arne Astrup","sponsor":"S-Biotek Holding ApS","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Alginic Acid Excipient","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Arne Astrup","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arne Astrup \/ S-Biotek Holding ApS","highestDevelopmentStatusID":"1","companyTruncated":"Arne Astrup \/ S-Biotek Holding ApS"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Public Offering","leadProduct":"ALN1001","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alaunos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Alaunos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pennington Biomedical Research Center","sponsor":"Quest Nutrition LLC","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Alpha-Cyclodextrin","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Pennington Biomedical Research Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pennington Biomedical Research Center \/ Quest Nutrition LLC","highestDevelopmentStatusID":"1","companyTruncated":"Pennington Biomedical Research Center \/ Quest Nutrition LLC"},{"orgOrder":0,"company":"Allysta Pharmaceuticals","sponsor":"INC Research Australia Pty Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ALY688-SR","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Allysta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allysta Pharmaceuticals \/ INC Research Australia Pty Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Allysta Pharmaceuticals \/ INC Research Australia Pty Ltd"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AMG 513","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"AMG171","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"AMG598","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AMG786","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Singapore Institute of Technology","sponsor":"AMILI Pte. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Amili Probiotic","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Singapore Institute of Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Singapore Institute of Technology \/ AMILI Pte. Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Singapore Institute of Technology \/ AMILI Pte. Ltd."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Amixea","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Changi General Hospital | SingHealth Polyclinics","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"AN 777","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Changi General Hospital | SingHealth Polyclinics","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Laboratories \/ Changi General Hospital | SingHealth Polyclinics"},{"orgOrder":0,"company":"Cifarma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BRAZIL","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Apetiviton BC","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Cifarma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cifarma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cifarma \/ Undisclosed"},{"orgOrder":0,"company":"Access Business Group","sponsor":"Radiant Research","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Apple","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Access Business Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Access Business Group \/ Radiant Research","highestDevelopmentStatusID":"1","companyTruncated":"Access Business Group \/ Radiant Research"},{"orgOrder":0,"company":"Nixol","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Apple Cider Vinegar Extract","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Nixol","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nixol \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nixol \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Aro-Inhbe","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ARO-INHBE","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-INHBE","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-INHBE","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-INHBE","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Comet Bio Inc.","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Arrabina P Prebiotic","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Comet Bio Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Comet Bio Inc. \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Comet Bio Inc. \/ Nutrasource"},{"orgOrder":0,"company":"Antag Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AT-7687","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Antag Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Antag Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antag Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Antag Therapeutic","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Series A Financing","leadProduct":"AT-7687","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Antag Therapeutic","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Antag Therapeutic \/ Versant Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Antag Therapeutic \/ Versant Ventures"},{"orgOrder":0,"company":"Antag Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AT-7687","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Antag Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Antag Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antag Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"University of Adelaide","sponsor":"Isagenix International LLC | Commonwealth Scientific and Industrial Research Organisation, Australia | Prolongevity Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"AUSTRALIA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Avocado Extract","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Adelaide","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Adelaide \/ Isagenix International LLC | Commonwealth Scientific and Industrial Research Organisation, Australia | Prolongevity Technologies","highestDevelopmentStatusID":"1","companyTruncated":"University of Adelaide \/ Isagenix International LLC | Commonwealth Scientific and Industrial Research Organisation, Australia | Prolongevity Technologies"},{"orgOrder":0,"company":"Ohr Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"AVR118","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Ohr Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ohr Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ohr Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Aymes International Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Aymes Actagain","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Aymes International Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aymes International Limited \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Aymes International Limited \/ Undisclosed"},{"orgOrder":0,"company":"Aymes International Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Aymes Amsterdam","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Aymes International Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aymes International Limited \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Aymes International Limited \/ Undisclosed"},{"orgOrder":0,"company":"Aymes International Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Aymes Cardiff","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Aymes International Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aymes International Limited \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Aymes International Limited \/ Undisclosed"},{"orgOrder":0,"company":"Aymes International Limited","sponsor":"Alison Clark Health and Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Aymes London","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Aymes International Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Powder","sponsorNew":"Aymes International Limited \/ Alison Clark Health and Nutrition","highestDevelopmentStatusID":"1","companyTruncated":"Aymes International Limited \/ Alison Clark Health and Nutrition"},{"orgOrder":0,"company":"Aymes International Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Aymes Monaco","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Aymes International Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aymes International Limited \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Aymes International Limited \/ Undisclosed"},{"orgOrder":0,"company":"Aymes International Limited","sponsor":"Alison Clark Health and Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Aymes Paris","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Aymes International Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Powder","sponsorNew":"Aymes International Limited \/ Alison Clark Health and Nutrition","highestDevelopmentStatusID":"1","companyTruncated":"Aymes International Limited \/ Alison Clark Health and Nutrition"},{"orgOrder":0,"company":"Aymes International Limited","sponsor":"Eat Well Now","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Aymes Prague","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Aymes International Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aymes International Limited \/ Eat Well Now","highestDevelopmentStatusID":"1","companyTruncated":"Aymes International Limited \/ Eat Well Now"},{"orgOrder":0,"company":"Aymes International Limited","sponsor":"Alison Clark Health and Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Aymes Rome","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Aymes International Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Powder","sponsorNew":"Aymes International Limited \/ Alison Clark Health and Nutrition","highestDevelopmentStatusID":"1","companyTruncated":"Aymes International Limited \/ Alison Clark Health and Nutrition"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"AZD2820","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Eccogene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AZD5004","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eccogene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eccogene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eccogene \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AZD5004","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AZD9550","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Lindenwood University","sponsor":"Increnovo, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Bacillus Coagulans GBI-30, 6086","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Lindenwood University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lindenwood University \/ Increnovo, LLC","highestDevelopmentStatusID":"1","companyTruncated":"Lindenwood University \/ Increnovo, LLC"},{"orgOrder":0,"company":"Universitair Ziekenhuis Brussel","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BELGIUM","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Back Side Of The Moon","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Universitair Ziekenhuis Brussel","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitair Ziekenhuis Brussel \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Universitair Ziekenhuis Brussel \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Mekelle University","sponsor":"Tigray Development Association | Mums for Mums | Tigray Health Research Institute | Tigray Health Bureau | UNICEF Tigray Office","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ETHIOPIA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Bahgina","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Mekelle University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mekelle University \/ Tigray Development Association | Mums for Mums | Tigray Health Research Institute | Tigray Health Bureau | UNICEF Tigray Office","highestDevelopmentStatusID":"1","companyTruncated":"Mekelle University \/ Tigray Development Association | Mums for Mums | Tigray Health Research Institute | Tigray Health Bureau | UNICEF Tigray Office"},{"orgOrder":0,"company":"Virginia Tech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BAM 15","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Virginia Tech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Tech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Virginia Tech \/ Undisclosed"},{"orgOrder":0,"company":"Cl\u00ednica Universidad de Navarra","sponsor":"Viscofan","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Barrita","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Cl\u00ednica Universidad de Navarra","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cl\u00ednica Universidad de Navarra \/ Viscofan","highestDevelopmentStatusID":"1","companyTruncated":"Cl\u00ednica Universidad de Navarra \/ Viscofan"},{"orgOrder":0,"company":"BrightGene New Bio-Medical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BGM0504","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"BrightGene New Bio-Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"BrightGene New Bio-Medical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BrightGene New Bio-Medical Technology \/ Undisclosed"},{"orgOrder":0,"company":"BrightGene Bio-Medical Technology Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BGM0504","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BrightGene Bio-Medical Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BrightGene Bio-Medical Technology Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BrightGene Bio-Medical Technology Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"BrightGene Bio-Medical Technology Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BGM0504","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BrightGene Bio-Medical Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BrightGene Bio-Medical Technology Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BrightGene Bio-Medical Technology Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"BrightGene Bio-Medical Technology Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BGM0504","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BrightGene Bio-Medical Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BrightGene Bio-Medical Technology Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BrightGene Bio-Medical Technology Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"BI 1820237","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Gubra","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"BI 1820237","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gubra \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Gubra","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"BI 3034701","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Gubra","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Gubra"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BI1356225","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Danisco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Bifidobacterium Animalis ssp. lactis 420","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Danisco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Danisco \/ Undisclosed"},{"orgOrder":0,"company":"Turku University Hospital","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FINLAND","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Bifidobacterium Bifidum","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Turku University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turku University Hospital \/ Lallemand Health Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Turku University Hospital \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"Morinaga Milk Industry Co., LTD","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Bifidobacterium Breve","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Morinaga Milk Industry Co., LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Morinaga Milk Industry Co., LTD \/ KGK Science","highestDevelopmentStatusID":"1","companyTruncated":"Morinaga Milk Industry Co., LTD \/ KGK Science"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Bifidobacterium Breve","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Shih Chien Huang","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Bifidobacterium Breve","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Shih Chien Huang","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Shih Chien Huang"},{"orgOrder":0,"company":"University College Cork","sponsor":"Atlantia Food Clinical Trials | CREMO SA","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"IRELAND","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Bifidobacterium Longum","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University College Cork","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University College Cork \/ Atlantia Food Clinical Trials | CREMO SA","highestDevelopmentStatusID":"1","companyTruncated":"University College Cork \/ Atlantia Food Clinical Trials | CREMO SA"},{"orgOrder":0,"company":"University of Manitoba","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Bifidobacterium Longum subp. Infantis R0033","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Manitoba \/ Lallemand Health Solutions","highestDevelopmentStatusID":"1","companyTruncated":"University of Manitoba \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"South Dakota State University","sponsor":"Sanford Health","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Bifidobacterium SPP","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"South Dakota State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"South Dakota State University \/ Sanford Health","highestDevelopmentStatusID":"1","companyTruncated":"South Dakota State University \/ Sanford Health"},{"orgOrder":0,"company":"Universidade do Porto","sponsor":"Center for Health Technology and Services Research | Vinoflavo","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"PORTUGAL","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Blackberry","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Universidade do Porto","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidade do Porto \/ Center for Health Technology and Services Research | Vinoflavo","highestDevelopmentStatusID":"6","companyTruncated":"Universidade do Porto \/ Center for Health Technology and Services Research | Vinoflavo"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BLX 0871","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolexis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Biolexis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BLX-7006","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolexis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biolexis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BLX-7006","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolexis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biolexis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BLX-7006","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolexis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biolexis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BLX-7006","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolexis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biolexis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Verifomics LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Broccoli","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Verifomics LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verifomics LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Verifomics LLC \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Glycemic Index Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Calcium Propionate","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Glycemic Index Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Glycemic Index Laboratories"},{"orgOrder":0,"company":"Assaf-Harofeh Medical Center","sponsor":"Tikun Olam","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Cannabis Oil","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Assaf-Harofeh Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oil","sponsorNew":"Assaf-Harofeh Medical Center \/ Tikun Olam","highestDevelopmentStatusID":"10","companyTruncated":"Assaf-Harofeh Medical Center \/ Tikun Olam"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Capolac","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"University of Copenhagen \/ GSK"},{"orgOrder":0,"company":"Laval University","sponsor":"OmniActive Health Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Capsimax","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laval University \/ OmniActive Health Technologies","highestDevelopmentStatusID":"11","companyTruncated":"Laval University \/ OmniActive Health Technologies"},{"orgOrder":0,"company":"NIZO Food Research","sponsor":"FrieslandCampina","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Casein","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"NIZO Food Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIZO Food Research \/ FrieslandCampina","highestDevelopmentStatusID":"1","companyTruncated":"NIZO Food Research \/ FrieslandCampina"},{"orgOrder":0,"company":"Dialpha","sponsor":"Naturalpha","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Cashew Apple Extract","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Dialpha","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dialpha \/ Naturalpha","highestDevelopmentStatusID":"1","companyTruncated":"Dialpha \/ Naturalpha"},{"orgOrder":0,"company":"Tory Hagen","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Centrum Silver Mens\\' Formula","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Tory Hagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tory Hagen \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"Tory Hagen \/ GSK"},{"orgOrder":0,"company":"University of Iceland","sponsor":"Mat\u00eds ohf | Reykjalundur Rehabilitation Center | Primex ehf","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ICELAND","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Chitosan Hydrochloride","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Iceland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Iceland \/ Mat\u00eds ohf | Reykjalundur Rehabilitation Center | Primex ehf","highestDevelopmentStatusID":"1","companyTruncated":"University of Iceland \/ Mat\u00eds ohf | Reykjalundur Rehabilitation Center | Primex ehf"},{"orgOrder":0,"company":"Chung Shan Medical University","sponsor":"TCI Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Citrus Reticulate Extract","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Chung Shan Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chung Shan Medical University \/ TCI Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Chung Shan Medical University \/ TCI Co., Ltd."},{"orgOrder":0,"company":"Cytoki Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CK-0045","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Cytoki Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytoki Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cytoki Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cytoki Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CK-0045","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Cytoki Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytoki Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cytoki Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ApexCPG LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CL19183","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"ApexCPG LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ApexCPG LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"ApexCPG LLC \/ Undisclosed"},{"orgOrder":0,"company":"Indonesia University","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDONESIA","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"CLA-Fortified Milk","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Indonesia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indonesia University \/ BASF","highestDevelopmentStatusID":"1","companyTruncated":"Indonesia University \/ BASF"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Clinolipid","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Clinolipid","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"West German Center of Diabetes and Health","sponsor":"Tchibo GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Coffee","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"West German Center of Diabetes and Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"West German Center of Diabetes and Health \/ Tchibo GmbH","highestDevelopmentStatusID":"1","companyTruncated":"West German Center of Diabetes and Health \/ Tchibo GmbH"},{"orgOrder":0,"company":"Clinical Nutrition Research Center, Illinois Institute of Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Coffee","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Clinical Nutrition Research Center, Illinois Institute of Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ Undisclosed"},{"orgOrder":0,"company":"Gut Health, UAB","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Colon Broom Premium Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Gut Health, UAB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Powder","sponsorNew":"Gut Health, UAB \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Gut Health, UAB \/ Citruslabs"},{"orgOrder":0,"company":"International Flavors and Fragrances","sponsor":"University of Colorado, Denver","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Colorado Diet","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"International Flavors and Fragrances","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Flavors and Fragrances \/ University of Colorado, Denver","highestDevelopmentStatusID":"1","companyTruncated":"International Flavors and Fragrances \/ University of Colorado, Denver"},{"orgOrder":0,"company":"M\u00e9decins Sans Fronti\u00e8res Netherlands","sponsor":"London School of Hygiene & Tropical Medicine | Nutriset | United Nations World Food Programme (WFP)","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Corn Soy Blend Oil","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"M\u00e9decins Sans Fronti\u00e8res Netherlands","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M\u00e9decins Sans Fronti\u00e8res Netherlands \/ London School of Hygiene & Tropical Medicine | Nutriset | United Nations World Food Programme (WFP)","highestDevelopmentStatusID":"1","companyTruncated":"M\u00e9decins Sans Fronti\u00e8res Netherlands \/ London School of Hygiene & Tropical Medicine | Nutriset | United Nations World Food Programme (WFP)"},{"orgOrder":0,"company":"Chia Tai Innovative Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"HONG KONG","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CPX101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Chia Tai Innovative Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Innovative Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Innovative Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Innovative Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"HONG KONG","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CPX101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Chia Tai Innovative Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Innovative Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Innovative Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kerry Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"IRELAND","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Cr-400","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Kerry Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kerry Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kerry Group \/ Undisclosed"},{"orgOrder":0,"company":"Oregon Research Behavioral Intervention Strategies, Inc.","sponsor":"Cravecrush | Oregon Behavioral Intervention Strategies, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Crave Crush","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Oregon Research Behavioral Intervention Strategies, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oregon Research Behavioral Intervention Strategies, Inc. \/ Cravecrush | Oregon Behavioral Intervention Strategies, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Oregon Research Behavioral Intervention Strategies, Inc. \/ Cravecrush | Oregon Behavioral Intervention Strategies, Inc."},{"orgOrder":0,"company":"Oregon Research Behavioral Intervention Strategies, Inc.","sponsor":"Cravecrush | Oregon Behavioral Intervention Strategies, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Crave Crush","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Oregon Research Behavioral Intervention Strategies, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oregon Research Behavioral Intervention Strategies, Inc. \/ Cravecrush | Oregon Behavioral Intervention Strategies, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Oregon Research Behavioral Intervention Strategies, Inc. \/ Cravecrush | Oregon Behavioral Intervention Strategies, Inc."},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Arla Foods | Kamuzu University of Health Sciences | Project Peanut Butter","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"C-RUSF","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Arla Foods | Kamuzu University of Health Sciences | Project Peanut Butter","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Arla Foods | Kamuzu University of Health Sciences | Project Peanut Butter"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Project Peanut Butter | Kamuzu University of Health Sciences | Balchem Corp","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"C-RUSF","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Project Peanut Butter | Kamuzu University of Health Sciences | Balchem Corp","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Project Peanut Butter | Kamuzu University of Health Sciences | Balchem Corp"},{"orgOrder":0,"company":"DSM Food Specialties","sponsor":"United Nations World Food Programme (WFP)","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"CSB Drum Dried","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"DSM Food Specialties","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DSM Food Specialties \/ United Nations World Food Programme (WFP)","highestDevelopmentStatusID":"1","companyTruncated":"DSM Food Specialties \/ United Nations World Food Programme (WFP)"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"QATAR","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Cubitan","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Texas A&M University","sponsor":"Curves International","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Curves Calcium","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Texas A&M University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Texas A&M University \/ Curves International","highestDevelopmentStatusID":"1","companyTruncated":"Texas A&M University \/ Curves International"},{"orgOrder":0,"company":"Chengdu DIAO Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DA-302168S","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Chengdu DIAO Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chengdu DIAO Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu DIAO Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu DIAO Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DA-302168S","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Chengdu DIAO Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chengdu DIAO Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu DIAO Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu DIAO Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DA-302168S","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Chengdu DIAO Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chengdu DIAO Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu DIAO Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu DIAO Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DA-302168S","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Chengdu DIAO Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chengdu DIAO Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu DIAO Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"University of Kansas","sponsor":"Dairy Management Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Dairy Product","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Kansas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Kansas \/ Dairy Management Inc.","highestDevelopmentStatusID":"1","companyTruncated":"University of Kansas \/ Dairy Management Inc."},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Arla Foods","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Dairy Protein","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Arla Foods","highestDevelopmentStatusID":"1","companyTruncated":"University of Copenhagen \/ Arla Foods"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"RUSSIA","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Dietressa","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Materia Medica Holding \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Materia Medica Holding \/ Undisclosed"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"RUSSIA","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Dietressa","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Materia Medica Holding \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Materia Medica Holding \/ Undisclosed"},{"orgOrder":0,"company":"4Life Research, LLC","sponsor":"Brigham Young University","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dihydrocapsiate","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"4Life Research, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4Life Research, LLC \/ Brigham Young University","highestDevelopmentStatusID":"1","companyTruncated":"4Life Research, LLC \/ Brigham Young University"},{"orgOrder":0,"company":"Ellen Evans","sponsor":"Kellogg Company","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dihydrocapsiate","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Ellen Evans","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ellen Evans \/ Kellogg Company","highestDevelopmentStatusID":"1","companyTruncated":"Ellen Evans \/ Kellogg Company"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Elecare","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Powder","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ELGN-2112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Elgan Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elgan Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Elgan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ELGN-2112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Elgan Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elgan Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Elgan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Eloralintide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Eloralintide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Arne Astrup","sponsor":"Biocare Copenhagen A\/S","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Encapsulated Nutrients","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Arne Astrup","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arne Astrup \/ Biocare Copenhagen A\/S","highestDevelopmentStatusID":"1","companyTruncated":"Arne Astrup \/ Biocare Copenhagen A\/S"},{"orgOrder":0,"company":"Arne Astrup","sponsor":"Biocare Copenhagen A\/S","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Encapsulated Nutrients","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Arne Astrup","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arne Astrup \/ Biocare Copenhagen A\/S","highestDevelopmentStatusID":"1","companyTruncated":"Arne Astrup \/ Biocare Copenhagen A\/S"},{"orgOrder":0,"company":"Anaiah Healthcare Pvt Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Energieshake","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Anaiah Healthcare Pvt Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anaiah Healthcare Pvt Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Anaiah Healthcare Pvt Ltd \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Children's Hospital Colorado | Mead Johnson Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Enfagrow Neuropro Toddler Nutrition","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Children's Hospital Colorado | Mead Johnson Nutrition","highestDevelopmentStatusID":"1","companyTruncated":"University of Colorado, Denver \/ Children's Hospital Colorado | Mead Johnson Nutrition"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Enriched Skimmilk With Vd","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Ensure","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ Abbott Laboratories"},{"orgOrder":0,"company":"Singapore General Hospital","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SINGAPORE","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Ensure Plus","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Singapore General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Singapore General Hospital \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Singapore General Hospital \/ Abbott Laboratories"},{"orgOrder":0,"company":"Laboratorios Ordesa","sponsor":"Peruvian Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Enteral Formula","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Laboratorios Ordesa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Ordesa \/ Peruvian Clinical Research","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Ordesa \/ Peruvian Clinical Research"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Enteral Nutrition","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Epitomee","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Epitomee","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Epitomee","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Epitomee \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Epitomee \/ Undisclosed"},{"orgOrder":0,"company":"Fondazione IRCCS Policlinico San Matteo","sponsor":"Leonardo Medica Srl","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Equikilon","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Fondazione IRCCS Policlinico San Matteo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fondazione IRCCS Policlinico San Matteo \/ Leonardo Medica Srl","highestDevelopmentStatusID":"1","companyTruncated":"Fondazione IRCCS Policlinico San Matteo \/ Leonardo Medica Srl"},{"orgOrder":0,"company":"ERX Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ERX1000","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"ERX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ERX Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ERX Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ERX-1000","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Pill","sponsorNew":"RespireRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"RespireRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Oregon Health and Science University","sponsor":"The Amino Company, LLC | National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Essential Amino Acid Protein Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Oregon Health and Science University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oregon Health and Science University \/ The Amino Company, LLC | National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"1","companyTruncated":"Oregon Health and Science University \/ The Amino Company, LLC | National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"Optimal Health Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"EZPAK","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Optimal Health Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Optimal Health Research \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Optimal Health Research \/ Undisclosed"},{"orgOrder":0,"company":"North-West University, South Africa","sponsor":"Global Alliance for Improved Nutrition | DSM Ltd | Unilever","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH AFRICA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Sodium Butyrate","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"North-West University, South Africa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"North-West University, South Africa \/ Global Alliance for Improved Nutrition | DSM Ltd | Unilever","highestDevelopmentStatusID":"1","companyTruncated":"North-West University, South Africa \/ Global Alliance for Improved Nutrition | DSM Ltd | Unilever"},{"orgOrder":0,"company":"S.LAB (SOLOWAYS)","sponsor":"Center of New Medical Technologies | Triangel Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"RUSSIA","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Fiber","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"S.LAB (SOLOWAYS)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"S.LAB (SOLOWAYS) \/ Center of New Medical Technologies | Triangel Scientific","highestDevelopmentStatusID":"1","companyTruncated":"S.LAB (SOLOWAYS) \/ Center of New Medical Technologies | Triangel Scientific"},{"orgOrder":0,"company":"S.LAB (SOLOWAYS)","sponsor":"Center of New Medical Technologies | Triangel Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"RUSSIA","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Fiber Supplement Group","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"S.LAB (SOLOWAYS)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"S.LAB (SOLOWAYS) \/ Center of New Medical Technologies | Triangel Scientific","highestDevelopmentStatusID":"1","companyTruncated":"S.LAB (SOLOWAYS) \/ Center of New Medical Technologies | Triangel Scientific"},{"orgOrder":0,"company":"Fytexia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Fiit-Ns","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Fytexia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fytexia \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Fytexia \/ Undisclosed"},{"orgOrder":0,"company":"Cook Children's Health Care System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Fish Oil Triglyceride","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Cook Children's Health Care System","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Cook Children's Health Care System \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cook Children's Health Care System \/ Undisclosed"},{"orgOrder":0,"company":"International Centre for Diarrhoeal Disease Research, Bangladesh","sponsor":"Suzuhiro Kamaboko Co., Ltd.,Japan","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BANGLADESH","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Fish Surimi Peptide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"International Centre for Diarrhoeal Disease Research, Bangladesh","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ Suzuhiro Kamaboko Co., Ltd.,Japan","highestDevelopmentStatusID":"6","companyTruncated":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ Suzuhiro Kamaboko Co., Ltd.,Japan"},{"orgOrder":0,"company":"University of Central Florida","sponsor":"Celsius Holdings, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Fitness Formula","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Central Florida","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Central Florida \/ Celsius Holdings, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"University of Central Florida \/ Celsius Holdings, Inc."},{"orgOrder":0,"company":"Nutrition Institute, Slovenia","sponsor":"Vizera d.o.o. | Frutarom Etol d.o.o. | European Regional Development Fund","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SLOVENIA","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Food Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nutrition Institute, Slovenia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrition Institute, Slovenia \/ Vizera d.o.o. | Frutarom Etol d.o.o. | European Regional Development Fund","highestDevelopmentStatusID":"1","companyTruncated":"Nutrition Institute, Slovenia \/ Vizera d.o.o. | Frutarom Etol d.o.o. | European Regional Development Fund"},{"orgOrder":0,"company":"Danone Specialized Nutrition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Fortimel","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Danone Specialized Nutrition","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danone Specialized Nutrition \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Danone Specialized Nutrition \/ Undisclosed"},{"orgOrder":0,"company":"Chinese University of Hong Kong","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"HONG KONG","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Fresubin Fibre","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Chinese University of Hong Kong","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese University of Hong Kong \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"1","companyTruncated":"Chinese University of Hong Kong \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"InQpharm Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Garcinia Cambogia Extract","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"InQpharm Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InQpharm Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InQpharm Group \/ Undisclosed"},{"orgOrder":0,"company":"Chemical Resources","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"GCB-70","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Chemical Resources","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chemical Resources \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chemical Resources \/ Undisclosed"},{"orgOrder":0,"company":"Musclegen Research, Inc.","sponsor":"WakeMed Bariatric Surgery & Weight Loss Center","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Genepro Generation 3 Protein","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Musclegen Research, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Musclegen Research, Inc. \/ WakeMed Bariatric Surgery & Weight Loss Center","highestDevelopmentStatusID":"1","companyTruncated":"Musclegen Research, Inc. \/ WakeMed Bariatric Surgery & Weight Loss Center"},{"orgOrder":0,"company":"Musclegen Research, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Genepro Protein","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Musclegen Research, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Musclegen Research, Inc. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Musclegen Research, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GFS202A","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"GenFleet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"InQpharm Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Glucosanol","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"InQpharm Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InQpharm Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"InQpharm Group \/ Undisclosed"},{"orgOrder":0,"company":"Glyscend Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"GLY-200","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glyscend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glyscend Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Glyscend Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Glyscend Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"GLY-200","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glyscend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glyscend Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Glyscend Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of Warsaw","sponsor":"Ausnutria Hyproca B.V.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"POLAND","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Goat Milk-Based Infant Formula","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Medical University of Warsaw","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of Warsaw \/ Ausnutria Hyproca B.V.","highestDevelopmentStatusID":"1","companyTruncated":"Medical University of Warsaw \/ Ausnutria Hyproca B.V."},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"AMOREPACIFIC CORPORATION","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Muscarinic acetylcholine receptor M2 (CHRM2)","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seoul National University Hospital \/ AMOREPACIFIC CORPORATION","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ AMOREPACIFIC CORPORATION"},{"orgOrder":0,"company":"Instituto Nacional de Salud Publica, Mexico","sponsor":"Mead Johnson Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"MEXICO","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Growing Milk","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Instituto Nacional de Salud Publica, Mexico","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Powder","sponsorNew":"Instituto Nacional de Salud Publica, Mexico \/ Mead Johnson Nutrition","highestDevelopmentStatusID":"1","companyTruncated":"Instituto Nacional de Salud Publica, Mexico \/ Mead Johnson Nutrition"},{"orgOrder":0,"company":"Gelesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"GSP3","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Gelesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gelesis \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Gelesis \/ Undisclosed"},{"orgOrder":0,"company":"Gubra","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"GUB014295","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":2.23,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.23,"dosageForm":"Injection","sponsorNew":"Gubra \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ AbbVie Inc"},{"orgOrder":0,"company":"Gubra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"GUB014295","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gubra \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Undisclosed"},{"orgOrder":0,"company":"Gubra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"GUB014295","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gubra \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Undisclosed"},{"orgOrder":0,"company":"Gubra","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"GUB014295","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gubra \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Quotient Sciences"},{"orgOrder":0,"company":"Modular Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"GUB014295","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Modular Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modular Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Modular Medical \/ Undisclosed"},{"orgOrder":0,"company":"Nexira","sponsor":"Analyze & Realize","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Gum Acacia","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nexira","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nexira \/ Analyze & Realize","highestDevelopmentStatusID":"1","companyTruncated":"Nexira \/ Analyze & Realize"},{"orgOrder":0,"company":"Texas Tech University","sponsor":"Breedlove Foods Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Harvest Lentil Vegetable Blend","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Texas Tech University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oil","sponsorNew":"Texas Tech University \/ Breedlove Foods Inc","highestDevelopmentStatusID":"1","companyTruncated":"Texas Tech University \/ Breedlove Foods Inc"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HDM1002","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HDM1002","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"HEC Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HEC88473","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"HEC Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"HEC Pharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HEC Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"High Energy, Low Volume Ons","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"High Protein Ons","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"High Protein Ons","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Beachbody","sponsor":"KGK Science | Glycemic Index Laboratories | MB Clinical Research and Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"High Protein, High Fiber Dietary Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Beachbody","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Powder","sponsorNew":"Beachbody \/ KGK Science | Glycemic Index Laboratories | MB Clinical Research and Consulting","highestDevelopmentStatusID":"1","companyTruncated":"Beachbody \/ KGK Science | Glycemic Index Laboratories | MB Clinical Research and Consulting"},{"orgOrder":0,"company":"Beachbody","sponsor":"Glycemic Index Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"High Protein, High Fiber Dietary Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Beachbody","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beachbody \/ Glycemic Index Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Beachbody \/ Glycemic Index Laboratories"},{"orgOrder":0,"company":"Hospital General Universitario Gregorio Mara\u00f1on","sponsor":"Maternal, Neonatal and Child Health Research Network | European Regional Development Fund | Instituto de Salud Carlos III","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"High Protein-Enriched Nutrition","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Hospital General Universitario Gregorio Mara\u00f1on","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital General Universitario Gregorio Mara\u00f1on \/ Maternal, Neonatal and Child Health Research Network | European Regional Development Fund | Instituto de Salud Carlos III","highestDevelopmentStatusID":"1","companyTruncated":"Hospital General Universitario Gregorio Mara\u00f1on \/ Maternal, Neonatal and Child Health Research Network | European Regional Development Fund | Instituto de Salud Carlos III"},{"orgOrder":0,"company":"Texas Tech University","sponsor":"Dymatize Enterprises, LLC | MuscleSound","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"High-Calorie Mass Gainer Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Texas Tech University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Texas Tech University \/ Dymatize Enterprises, LLC | MuscleSound","highestDevelopmentStatusID":"1","companyTruncated":"Texas Tech University \/ Dymatize Enterprises, LLC | MuscleSound"},{"orgOrder":0,"company":"Danone Specialized Nutrition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"High-Energy, Low-Volume Ons","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Danone Specialized Nutrition","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danone Specialized Nutrition \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Danone Specialized Nutrition \/ Undisclosed"},{"orgOrder":0,"company":"The Hospital for Sick Children","sponsor":"Ministry of Health, Malawi | Schlumberger Foundation | Nutriset | Friends of Sick Children, Malawi","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"High-protein RUTF","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"The Hospital for Sick Children","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Powder","sponsorNew":"The Hospital for Sick Children \/ Ministry of Health, Malawi | Schlumberger Foundation | Nutriset | Friends of Sick Children, Malawi","highestDevelopmentStatusID":"1","companyTruncated":"The Hospital for Sick Children \/ Ministry of Health, Malawi | Schlumberger Foundation | Nutriset | Friends of Sick Children, Malawi"},{"orgOrder":0,"company":"Metabolic Technologies","sponsor":"Iowa State University","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"HMB","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Metabolic Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metabolic Technologies \/ Iowa State University","highestDevelopmentStatusID":"1","companyTruncated":"Metabolic Technologies \/ Iowa State University"},{"orgOrder":0,"company":"Integrated Reproductive Maternal Newborn & Child Health and Nutrition Program, Punjab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"PAKISTAN","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Home Based Food","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Integrated Reproductive Maternal Newborn & Child Health and Nutrition Program, Punjab","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integrated Reproductive Maternal Newborn & Child Health and Nutrition Program, Punjab \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Integrated Reproductive Maternal Newborn & Child Health and Nutrition Program, Punjab \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HRS-4729","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HRS-5817","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kailera Therapeutics","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Series A Financing","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Kailera Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.40000000000000002,"dosageForm":"Injection","sponsorNew":"Kailera Therapeutics \/ Atlas Venture","highestDevelopmentStatusID":"10","companyTruncated":"Kailera Therapeutics \/ Atlas Venture"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"HS-10535","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Hansoh Pharma","amount2":2.0099999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.0099999999999998,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Hansoh Pharma \/ Merck & Co"},{"orgOrder":0,"company":"35Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HS235","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"35Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"35Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"35Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Glaceum","sponsor":"Gangnam Severance Hospital | Seoul National University Bundang Hospital | Korea University Anam Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Gangnam Severance Hospital | Seoul National University Bundang Hospital | Korea University Anam Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Gangnam Severance Hospital | Seoul National University Bundang Hospital | Korea University Anam Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center"},{"orgOrder":0,"company":"Glaceum","sponsor":"Kyungpook National University Hospital | Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Kyungpook National University Hospital | Seoul National University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Kyungpook National University Hospital | Seoul National University Hospital"},{"orgOrder":0,"company":"Glaceum","sponsor":"Seoul National University Hospital | Kyungpook National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Seoul National University Hospital | Kyungpook National University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Seoul National University Hospital | Kyungpook National University Hospital"},{"orgOrder":0,"company":"Glaceum","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Seoul National University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Seoul National University Hospital"},{"orgOrder":0,"company":"Glaceum","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Seoul National University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Seoul National University Hospital"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Mead Johnson Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Human Milk Fortifier","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Mead Johnson Nutrition","highestDevelopmentStatusID":"1","companyTruncated":"Peking Union Medical College Hospital \/ Mead Johnson Nutrition"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Human Milk Oligosaccharide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meiji Seika Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Meiji Seika Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Hy.D Calcifediol","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Peking Union Medical College Hospital | First Affiliated Hospital Xi'an Jiaotong University","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HY-2003","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Peking Union Medical College Hospital | First Affiliated Hospital Xi'an Jiaotong University","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Peking Union Medical College Hospital | First Affiliated Hospital Xi'an Jiaotong University"},{"orgOrder":0,"company":"Intarcia","sponsor":"i2o Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"i2o-105","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Intarcia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intarcia \/ i2o Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Intarcia \/ i2o Therapeutics"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"IC-100-08","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"IC-100-08","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Yunovia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ID110521156","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Yunovia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yunovia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Yunovia \/ Undisclosed"},{"orgOrder":0,"company":"Chung Shan Medical University","sponsor":"Itsway Biotech Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"I-Fiber Pearl","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Chung Shan Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chung Shan Medical University \/ Itsway Biotech Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Chung Shan Medical University \/ Itsway Biotech Inc."},{"orgOrder":0,"company":"Immunis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunis \/ Undisclosed"},{"orgOrder":0,"company":"Immunis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunis \/ Undisclosed"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"FrieslandCampina","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Intrinsically Labelled Milk Protein","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ FrieslandCampina","highestDevelopmentStatusID":"1","companyTruncated":"Maastricht University Medical Center \/ FrieslandCampina"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Analyze & Realize","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"IRELAND","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"IQP-AE-103","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Perrigo Company plc \/ Analyze & Realize","highestDevelopmentStatusID":"1","companyTruncated":"Perrigo Company plc \/ Analyze & Realize"},{"orgOrder":0,"company":"InQpharm Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"IQP-AE-103","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"InQpharm Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InQpharm Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"InQpharm Group \/ Undisclosed"},{"orgOrder":0,"company":"InQpharm Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"IQP-AK-102","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"InQpharm Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InQpharm Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InQpharm Group \/ Undisclosed"},{"orgOrder":0,"company":"InQpharm Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"IQP-LU-104","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"InQpharm Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InQpharm Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"InQpharm Group \/ Undisclosed"},{"orgOrder":0,"company":"InQpharm Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"IQP-VV-102","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"InQpharm Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InQpharm Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InQpharm Group \/ Undisclosed"},{"orgOrder":0,"company":"Beneo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Isomaltulose","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Beneo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beneo \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Beneo \/ Undisclosed"},{"orgOrder":0,"company":"Tel Aviv Sourasky Medical Center (Ichilov Hospital)","sponsor":"Beneo","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Isomaltulose","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Tel Aviv Sourasky Medical Center (Ichilov Hospital)","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tel Aviv Sourasky Medical Center (Ichilov Hospital) \/ Beneo","highestDevelopmentStatusID":"10","companyTruncated":"Tel Aviv Sourasky Medical Center (Ichilov Hospital) \/ Beneo"},{"orgOrder":0,"company":"Griffin Hospital","sponsor":"ISOThrive Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Isothrive Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Griffin Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Griffin Hospital \/ ISOThrive Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Griffin Hospital \/ ISOThrive Inc."},{"orgOrder":0,"company":"Meddoc","sponsor":"Tine | Norwegian University of Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Jarlsberg Cheese","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Meddoc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meddoc \/ Tine | Norwegian University of Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Meddoc \/ Tine | Norwegian University of Life Sciences"},{"orgOrder":0,"company":"Griffin Hospital","sponsor":"NSA, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Juice Plus","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Griffin Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Griffin Hospital \/ NSA, LLC","highestDevelopmentStatusID":"1","companyTruncated":"Griffin Hospital \/ NSA, LLC"},{"orgOrder":0,"company":"University of Memphis","sponsor":"USANA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Jump Start Nutritional Program","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Memphis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Pill","sponsorNew":"University of Memphis \/ USANA Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"University of Memphis \/ USANA Health Sciences"},{"orgOrder":0,"company":"Zhejiang Kanglaite Pharmaceutical Co.Ltd","sponsor":"H & J CRO International","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Kanglaite","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Zhejiang Kanglaite Pharmaceutical Co.Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang Kanglaite Pharmaceutical Co.Ltd \/ H & J CRO International","highestDevelopmentStatusID":"11","companyTruncated":"Zhejiang Kanglaite Pharmaceutical Co.Ltd \/ H & J CRO International"},{"orgOrder":0,"company":"Kwang Dong Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"KD101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Kwang Dong Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kwang Dong Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kwang Dong Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Griffin Hospital","sponsor":"Kind LLC","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Kind Bars","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Griffin Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Griffin Hospital \/ Kind LLC","highestDevelopmentStatusID":"1","companyTruncated":"Griffin Hospital \/ Kind LLC"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KN069","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alphamab Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alphamab Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Hiroshima University","sponsor":"Marukome Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Koji-Extracted Beverage Fermented With Pediococcus Pentosaceus Lp28","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Hiroshima University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hiroshima University \/ Marukome Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Hiroshima University \/ Marukome Co., Ltd."},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Glucomannan","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Gel","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Konjac Noodles","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Gel","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Kintai Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"KTX-0200","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Kintai Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintai Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Kintai Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indonesia University","sponsor":"Medika Natura","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDONESIA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Labisia Pumila Aqueous Ethanolic Standardized Extract","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Indonesia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indonesia University \/ Medika Natura","highestDevelopmentStatusID":"8","companyTruncated":"Indonesia University \/ Medika Natura"},{"orgOrder":0,"company":"SunWay Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"SunWay Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunWay Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"SunWay Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei CNCM I-1572","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofar Spa \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sofar Spa \/ Undisclosed"},{"orgOrder":0,"company":"Fudan University","sponsor":"Inner Mongolia Yili Industrial Group Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei K56","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Fudan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fudan University \/ Inner Mongolia Yili Industrial Group Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Fudan University \/ Inner Mongolia Yili Industrial Group Co., Ltd"},{"orgOrder":0,"company":"Fudan University","sponsor":"Inner Mongolia Yili Industrial Group Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei K56","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Fudan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fudan University \/ Inner Mongolia Yili Industrial Group Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Fudan University \/ Inner Mongolia Yili Industrial Group Co., Ltd"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Lundbeck Foundation | Arla Foods","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei Ssp Paracasei F19","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Lundbeck Foundation | Arla Foods","highestDevelopmentStatusID":"1","companyTruncated":"University of Copenhagen \/ Lundbeck Foundation | Arla Foods"},{"orgOrder":0,"company":"Hospital de la Santa Creu i Sant Pau","sponsor":"AB Biotics","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Plantarum Probiotic","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Hospital de la Santa Creu i Sant Pau","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital de la Santa Creu i Sant Pau \/ AB Biotics","highestDevelopmentStatusID":"1","companyTruncated":"Hospital de la Santa Creu i Sant Pau \/ AB Biotics"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Novo Nordisk | Aarhus University Hospital | Riisfort","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Lake Ester","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Aarhus \/ Novo Nordisk | Aarhus University Hospital | Riisfort","highestDevelopmentStatusID":"1","companyTruncated":"University of Aarhus \/ Novo Nordisk | Aarhus University Hospital | Riisfort"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LB64640","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago | Northwestern University Feinberg School of Medicine | Mead Johnson Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"LCPUFA Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ Ann & Robert H Lurie Children's Hospital of Chicago | Northwestern University Feinberg School of Medicine | Mead Johnson Nutrition","highestDevelopmentStatusID":"1","companyTruncated":"Endeavor Health \/ Ann & Robert H Lurie Children's Hospital of Chicago | Northwestern University Feinberg School of Medicine | Mead Johnson Nutrition"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"L-Cysteine Hydrochloride","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University College Cork","sponsor":"Novozymes","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"IRELAND","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Limosilactobacillus Reuteri","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University College Cork","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University College Cork \/ Novozymes","highestDevelopmentStatusID":"1","companyTruncated":"University College Cork \/ Novozymes"},{"orgOrder":0,"company":"Valbiotis","sponsor":"University Hospital, Clermont-Ferrand | Universit\u00e9 Blaise Pascal, Clermont-Ferrand | Biofortis M\u00e9rieux Nutriscience","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Lipidrive","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ University Hospital, Clermont-Ferrand | Universit\u00e9 Blaise Pascal, Clermont-Ferrand | Biofortis M\u00e9rieux Nutriscience","highestDevelopmentStatusID":"7","companyTruncated":"Valbiotis \/ University Hospital, Clermont-Ferrand | Universit\u00e9 Blaise Pascal, Clermont-Ferrand | Biofortis M\u00e9rieux Nutriscience"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Liposomal Process B Vitamin C","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"InQpharm Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Litramine","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"InQpharm Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InQpharm Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"InQpharm Group \/ Undisclosed"},{"orgOrder":0,"company":"InQpharm Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Litramine","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"InQpharm Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InQpharm Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"InQpharm Group \/ Undisclosed"},{"orgOrder":0,"company":"InQpharm Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Litramine","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"InQpharm Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InQpharm Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"InQpharm Group \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"LMT1-48","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"University of California, Davis","sponsor":"Family Health International 360 | International Centre for Diarrhoeal Disease Research, Bangladesh | World Mission Prayer League","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"LNS-PLW","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of California, Davis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Sachet","sponsorNew":"University of California, Davis \/ Family Health International 360 | International Centre for Diarrhoeal Disease Research, Bangladesh | World Mission Prayer League","highestDevelopmentStatusID":"1","companyTruncated":"University of California, Davis \/ Family Health International 360 | International Centre for Diarrhoeal Disease Research, Bangladesh | World Mission Prayer League"},{"orgOrder":0,"company":"Tufts University","sponsor":"Massachusetts General Hospital | Global Food & Nutrition Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Locally-Prepared Bar","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Tufts University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tufts University \/ Massachusetts General Hospital | Global Food & Nutrition Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Tufts University \/ Massachusetts General Hospital | Global Food & Nutrition Inc."},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"FrieslandCampina","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Low Glycated Milk Protein","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ FrieslandCampina","highestDevelopmentStatusID":"1","companyTruncated":"Maastricht University Medical Center \/ FrieslandCampina"},{"orgOrder":0,"company":"Fondazione IRCCS Ca' Granda","sponsor":"Humana","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Low Protein Formula","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Fondazione IRCCS Ca' Granda","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fondazione IRCCS Ca' Granda \/ Humana","highestDevelopmentStatusID":"1","companyTruncated":"Fondazione IRCCS Ca' Granda \/ Humana"},{"orgOrder":0,"company":"University of Liverpool","sponsor":"University of Surrey | Perspectum","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Low-Calorie Diet","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Liverpool","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Liverpool \/ University of Surrey | Perspectum","highestDevelopmentStatusID":"1","companyTruncated":"University of Liverpool \/ University of Surrey | Perspectum"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Cambridge Weight Plan","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Low-Calorie Diet","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College London \/ Cambridge Weight Plan","highestDevelopmentStatusID":"1","companyTruncated":"Imperial College London \/ Cambridge Weight Plan"},{"orgOrder":0,"company":"Kemin Foods LC","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Lutein","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Kemin Foods LC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kemin Foods LC \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Kemin Foods LC \/ Royal DSM"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"LY3457263","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LY3537031","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"KeyBioscience","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Expanded Collaboration","leadProduct":"LY3541105","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"KeyBioscience","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1.3999999999999999,"dosageForm":"Undisclosed","sponsorNew":"KeyBioscience \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"KeyBioscience \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"LY3541105","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LY3549492","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LY3841136","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LY3841136","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LY3841136","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LY3841136","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LY3971297","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LY4086940","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LY6249492","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Jeff Golini","sponsor":"All American Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Lyzme","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Jeff Golini","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jeff Golini \/ All American Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Jeff Golini \/ All American Pharmaceutical"},{"orgOrder":0,"company":"Sheba Medical Center","sponsor":"Naveh Pharma (1996) Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Magnesium Oxide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Sheba Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sheba Medical Center \/ Naveh Pharma (1996) Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Sheba Medical Center \/ Naveh Pharma (1996) Ltd."},{"orgOrder":0,"company":"FrieslandCampina","sponsor":"University of Ibadan","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Maize","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"FrieslandCampina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FrieslandCampina \/ University of Ibadan","highestDevelopmentStatusID":"1","companyTruncated":"FrieslandCampina \/ University of Ibadan"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Maridebart Cafraglutide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Maridebart Cafraglutide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Maridebart Cafraglutide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Maridebart Cafraglutide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Maridebart Cafraglutide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Maridebart Cafraglutide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MBL949","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MBX 4291","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"MBX Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MBX 4291","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"MBX Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Radella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MD-18","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Radella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Radella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clinical Nutrition Research Center, Illinois Institute of Technology","sponsor":"California Strawberry Commission","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Meal","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Clinical Nutrition Research Center, Illinois Institute of Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ California Strawberry Commission","highestDevelopmentStatusID":"1","companyTruncated":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ California Strawberry Commission"},{"orgOrder":0,"company":"Bayside Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Meal","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Bayside Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayside Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bayside Health \/ Undisclosed"},{"orgOrder":0,"company":"Bonn Education Association for Dietetics r.A., Cologne, Germany","sponsor":"FomMed HealthCare AG","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Meal Replacement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Bonn Education Association for Dietetics r.A., Cologne, Germany","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bonn Education Association for Dietetics r.A., Cologne, Germany \/ FomMed HealthCare AG","highestDevelopmentStatusID":"10","companyTruncated":"Bonn Education Association for Dietetics r.A., Cologne, Germany \/ FomMed HealthCare AG"},{"orgOrder":0,"company":"University of Memphis","sponsor":"USANA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Meal Replacements & Supplements","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Memphis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Memphis \/ USANA Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"University of Memphis \/ USANA Health Sciences"},{"orgOrder":0,"company":"University of Exeter","sponsor":"Marlow Foods Ltd | NIHR Exeter Clinical Research Facility","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Meat","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Exeter","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Exeter \/ Marlow Foods Ltd | NIHR Exeter Clinical Research Facility","highestDevelopmentStatusID":"1","companyTruncated":"University of Exeter \/ Marlow Foods Ltd | NIHR Exeter Clinical Research Facility"},{"orgOrder":0,"company":"piero portincasa","sponsor":"University of Bari Aldo Moro | Uppsala University | Fundaci\u00f3 Eurecat | ADPD | University of Coimbra | AGDCENTRO ASSOCIACAO DE GINASTICA DO CENTRO | INSTITUTO POLITECNICO DE VIANA DE CASTELO | Consiglio Nazionale delle Ricerche, Italy | Technical Universit","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"MeD Enriched with Mushrooms","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"piero portincasa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"piero portincasa \/ University of Bari Aldo Moro | Uppsala University | Fundaci\u00f3 Eurecat | ADPD | University of Coimbra | AGDCENTRO ASSOCIACAO DE GINASTICA DO CENTRO | INSTITUTO POLITECNICO DE VIANA DE CASTELO | Consiglio Nazionale delle Ricerche, Italy | Technical Universit","highestDevelopmentStatusID":"1","companyTruncated":"piero portincasa \/ University of Bari Aldo Moro | Uppsala University | Fundaci\u00f3 Eurecat | ADPD | University of Coimbra | AGDCENTRO ASSOCIACAO DE GINASTICA DO CENTRO | INSTITUTO POLITECNICO DE VIANA DE CASTELO | Consiglio Nazionale delle Ricerche, Italy | Technical Universit"},{"orgOrder":0,"company":"Northwest Health","sponsor":"Neolac Inc dba Medolac Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Medolac Human Milk Based Human Milk Fortifier","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Northwest Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwest Health \/ Neolac Inc dba Medolac Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Northwest Health \/ Neolac Inc dba Medolac Laboratories"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Metsera","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"MET-097","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Metsera","highestDevelopmentStatusID":"6","companyTruncated":"Amneal Pharmaceuticals \/ Metsera"},{"orgOrder":0,"company":"Metsera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MET-097i","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Metsera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Undisclosed"},{"orgOrder":0,"company":"Metsera","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MET-097i","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Metsera \/ Altasciences Company Inc","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Metsera","sponsor":"Wellington Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Series B Financing","leadProduct":"MET-097i","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0.22,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.22,"dosageForm":"Injection","sponsorNew":"Metsera \/ Wellington Management","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Wellington Management"},{"orgOrder":0,"company":"NuBiyota","sponsor":"Glycemic Index Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MET-2","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NuBiyota","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NuBiyota \/ Glycemic Index Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"NuBiyota \/ Glycemic Index Laboratories"},{"orgOrder":0,"company":"Metsera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MET233","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metsera \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Metsera \/ Undisclosed"},{"orgOrder":0,"company":"Metsera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MET233","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Metsera \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Metsera \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Project Peanut Butter | Ministry of Health and Sanitation, Sierra Leone | Arla Foods Ingredients | The Danish Dairy Research Foundation, Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"MFGM-RUTF","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Project Peanut Butter | Ministry of Health and Sanitation, Sierra Leone | Arla Foods Ingredients | The Danish Dairy Research Foundation, Denmark","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Project Peanut Butter | Ministry of Health and Sanitation, Sierra Leone | Arla Foods Ingredients | The Danish Dairy Research Foundation, Denmark"},{"orgOrder":0,"company":"Bonn Education Association for Dietetics r.A., Cologne, Germany","sponsor":"St. Franziskus Hospital | University of Bonn | FormMed HealthCare AG","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Micronutrient Probiotic Combination","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Bonn Education Association for Dietetics r.A., Cologne, Germany","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bonn Education Association for Dietetics r.A., Cologne, Germany \/ St. Franziskus Hospital | University of Bonn | FormMed HealthCare AG","highestDevelopmentStatusID":"10","companyTruncated":"Bonn Education Association for Dietetics r.A., Cologne, Germany \/ St. Franziskus Hospital | University of Bonn | FormMed HealthCare AG"},{"orgOrder":0,"company":"Amazentis","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mitopure","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Amazentis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amazentis \/ KGK Science","highestDevelopmentStatusID":"1","companyTruncated":"Amazentis \/ KGK Science"},{"orgOrder":0,"company":"Clinical Nutrition Research Center, Illinois Institute of Technology","sponsor":"USDA Beltsville Human Nutrition Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Mixed Berries","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Clinical Nutrition Research Center, Illinois Institute of Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ USDA Beltsville Human Nutrition Research Center","highestDevelopmentStatusID":"1","companyTruncated":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ USDA Beltsville Human Nutrition Research Center"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Metabolexis","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MLX7000","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolexis Therapeutics \/ Metabolexis","highestDevelopmentStatusID":"4","companyTruncated":"Biolexis Therapeutics \/ Metabolexis"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Tel Aviv Sourasky Medical Center (Ichilov Hospital)","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"MOD-6031","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OPKO Health \/ Tel Aviv Sourasky Medical Center (Ichilov Hospital)","highestDevelopmentStatusID":"6","companyTruncated":"OPKO Health \/ Tel Aviv Sourasky Medical Center (Ichilov Hospital)"},{"orgOrder":0,"company":"Galilee CBR","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Multivitamin","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Galilee CBR","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galilee CBR \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Galilee CBR \/ Undisclosed"},{"orgOrder":0,"company":"Exerkine Corporation","sponsor":"University of Waterloo","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Muscle5","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Exerkine Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exerkine Corporation \/ University of Waterloo","highestDevelopmentStatusID":"10","companyTruncated":"Exerkine Corporation \/ University of Waterloo"},{"orgOrder":0,"company":"Shanghai Minwei Biotechnology Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MWN109","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Shanghai Minwei Biotechnology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Minwei Biotechnology Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Minwei Biotechnology Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"University of Manchester","sponsor":"Cargill","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Natural High Potency Sweetener From Leaf Extract","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Manchester","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Manchester \/ Cargill","highestDevelopmentStatusID":"1","companyTruncated":"University of Manchester \/ Cargill"},{"orgOrder":0,"company":"Orexigen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"NB32","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Orexigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orexigen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orexigen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Meiji Health Science and Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Nelumbo Nucifera Leaf Extract","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Shanghai Meiji Health Science and Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Meiji Health Science and Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Meiji Health Science and Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"KGK Science","sponsor":"Arthur Andrew Medical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Neoprinol","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ Arthur Andrew Medical","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ Arthur Andrew Medical"},{"orgOrder":0,"company":"Lactalis","sponsor":"University Hospital, Toulouse | University of Lille Nord de France | National Research Agency, France","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"New Delical Formula","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lactalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lactalis \/ University Hospital, Toulouse | University of Lille Nord de France | National Research Agency, France","highestDevelopmentStatusID":"8","companyTruncated":"Lactalis \/ University Hospital, Toulouse | University of Lille Nord de France | National Research Agency, France"},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NG101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Neurogastrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurogastrx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurogastrx \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"NNC 0070-0002-0453","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"NNC0165-1562","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"NNC0165-1875","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"NNC0174-0833","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"NNC0174-0833","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"NNC0174-0833","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"NNC0174-0833","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"NNC0174-0833","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"NNC0174-0833","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"NNC0174-0833","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NNC0174-0833","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NNC0174-1213 A","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"NNC0247-0829","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"NNC0480-0389","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NNC0487-0111","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NNC0487-0111","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NNC0487-0111","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NNC0487-0111","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NNC0487-0111","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NNC0487-0111","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NNC0519-0130","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NNC0519-0130","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NNC0519-0130","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NNC0638-0355","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NNC0662-0419","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NNC0662-0419","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"NNC9204-0530","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"NNC9204-0530","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"NNC9204-0530","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"NNC9204-1177","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"NNC9204-1177","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"NNC9204-1177","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"NNC9204-1706","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"NNC9204-1706","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NO-13065","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Otsuka Pharmaceutical \/ Celerion"},{"orgOrder":0,"company":"Canadian Center for Functional Medicine","sponsor":"University of British Columbia | InovoBiologic Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Novel Fibre Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Canadian Center for Functional Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian Center for Functional Medicine \/ University of British Columbia | InovoBiologic Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Canadian Center for Functional Medicine \/ University of British Columbia | InovoBiologic Inc."},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"NPC-02","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nobelpharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nobelpharma \/ Undisclosed"},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"NPC-02","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nobelpharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nobelpharma \/ Undisclosed"},{"orgOrder":0,"company":"Nutrinia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"NTRA-2112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Nutrinia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrinia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nutrinia \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Numeta G13 E","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Kalbe International Pte. Ltd","sponsor":"Persahabatan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SINGAPORE","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Nutrican","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Kalbe International Pte. Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Kalbe International Pte. Ltd \/ Persahabatan Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Kalbe International Pte. Ltd \/ Persahabatan Hospital"},{"orgOrder":0,"company":"Indonesia University","sponsor":"Wageningen University | FrieslandCampina","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDONESIA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Nutrient-Dense Drink","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Indonesia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indonesia University \/ Wageningen University | FrieslandCampina","highestDevelopmentStatusID":"1","companyTruncated":"Indonesia University \/ Wageningen University | FrieslandCampina"},{"orgOrder":0,"company":"Roquette Freres","sponsor":"Sprim Advanced Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Roquette Freres","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roquette Freres \/ Sprim Advanced Life Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Roquette Freres \/ Sprim Advanced Life Sciences"},{"orgOrder":0,"company":"Nealth Sarl","sponsor":"Roquette Freres","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"NUTRIOSE FB06","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Nealth Sarl","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nealth Sarl \/ Roquette Freres","highestDevelopmentStatusID":"6","companyTruncated":"Nealth Sarl \/ Roquette Freres"},{"orgOrder":0,"company":"University of Reading","sponsor":"Roquette Freres","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"NUTRIOSE FB06","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Reading","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Reading \/ Roquette Freres","highestDevelopmentStatusID":"1","companyTruncated":"University of Reading \/ Roquette Freres"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Health Insurance Fund of Research Council Faroe Islands | National Hospital of the Faroe Islands | Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Nutrition","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Health Insurance Fund of Research Council Faroe Islands | National Hospital of the Faroe Islands | Nestle Health Sciences SA","highestDevelopmentStatusID":"1","companyTruncated":"University of Copenhagen \/ Health Insurance Fund of Research Council Faroe Islands | National Hospital of the Faroe Islands | Nestle Health Sciences SA"},{"orgOrder":0,"company":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine","sponsor":"Shanghai University of Sports National Science Park | Yinhang Community Health Service Center of Yangpu District | Dinghai Community Health Service Center of Yangpu District | Kongjiang Community Health Service Center of Yangpu District | Daqiao Community","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Nutritional Meal","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine \/ Shanghai University of Sports National Science Park | Yinhang Community Health Service Center of Yangpu District | Dinghai Community Health Service Center of Yangpu District | Kongjiang Community Health Service Center of Yangpu District | Daqiao Community","highestDevelopmentStatusID":"1","companyTruncated":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine \/ Shanghai University of Sports National Science Park | Yinhang Community Health Service Center of Yangpu District | Dinghai Community Health Service Center of Yangpu District | Kongjiang Community Health Service Center of Yangpu District | Daqiao Community"},{"orgOrder":0,"company":"Children's Hospital of Chongqing Medical University","sponsor":"Anhui Provincial Children's Hospital | Baoji Maternity and Child Healthcare Hospital | Chengdu Women's and Children's Central Hospital | Guiyang Maternity and Child Health Care Hospital | Guangzhou Women and Children's Medical Center | Hunan Children's Ho","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Children's Hospital of Chongqing Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Chongqing Medical University \/ Anhui Provincial Children's Hospital | Baoji Maternity and Child Healthcare Hospital | Chengdu Women's and Children's Central Hospital | Guiyang Maternity and Child Health Care Hospital | Guangzhou Women and Children's Medical Center | Hunan Children's Ho","highestDevelopmentStatusID":"1","companyTruncated":"Children's Hospital of Chongqing Medical University \/ Anhui Provincial Children's Hospital | Baoji Maternity and Child Healthcare Hospital | Chengdu Women's and Children's Central Hospital | Guiyang Maternity and Child Health Care Hospital | Guangzhou Women and Children's Medical Center | Hunan Children's Ho"},{"orgOrder":0,"company":"University of Erlangen-N\u00fcrnberg Medical School","sponsor":"Nutricia","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Erlangen-N\u00fcrnberg Medical School","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Erlangen-N\u00fcrnberg Medical School \/ Nutricia","highestDevelopmentStatusID":"1","companyTruncated":"University of Erlangen-N\u00fcrnberg Medical School \/ Nutricia"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Undisclosed"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Pharmanex","sponsor":"Texas Diabetes & Endocrinology, P.A. | Utah State University","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Nutritional Supplement Blend","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Pharmanex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmanex \/ Texas Diabetes & Endocrinology, P.A. | Utah State University","highestDevelopmentStatusID":"1","companyTruncated":"Pharmanex \/ Texas Diabetes & Endocrinology, P.A. | Utah State University"},{"orgOrder":0,"company":"Universitair Ziekenhuis Brussel","sponsor":"Baxter Healthcare Corporation | Nutricia Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BELGIUM","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Nutritional Therapy","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Universitair Ziekenhuis Brussel","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitair Ziekenhuis Brussel \/ Baxter Healthcare Corporation | Nutricia Inc","highestDevelopmentStatusID":"1","companyTruncated":"Universitair Ziekenhuis Brussel \/ Baxter Healthcare Corporation | Nutricia Inc"},{"orgOrder":0,"company":"New York Obesity and Nutrition Research Center","sponsor":"PepsiCo","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Oatmeal","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"New York Obesity and Nutrition Research Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New York Obesity and Nutrition Research Center \/ PepsiCo","highestDevelopmentStatusID":"1","companyTruncated":"New York Obesity and Nutrition Research Center \/ PepsiCo"},{"orgOrder":0,"company":"Queen Margaret University","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Oatwell28 Oatwell Original Powder","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Queen Margaret University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Powder","sponsorNew":"Queen Margaret University \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Queen Margaret University \/ Royal DSM"},{"orgOrder":0,"company":"Catalysis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Obex","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Catalysis \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Catalysis \/ Undisclosed"},{"orgOrder":0,"company":"Catalysis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Obex","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalysis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Catalysis \/ Undisclosed"},{"orgOrder":0,"company":"Catalysis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Obex","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalysis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Catalysis \/ Undisclosed"},{"orgOrder":0,"company":"Oncocross","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OC514","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Oncocross","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncocross \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oncocross \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Olive","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Miami Research Associates","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"OM3-Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Miami Research Associates","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Miami Research Associates"},{"orgOrder":0,"company":"Herlev and Gentofte Hospital","sponsor":"Nutricia Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Omega-3 Protein","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Herlev and Gentofte Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Herlev and Gentofte Hospital \/ Nutricia Inc","highestDevelopmentStatusID":"1","companyTruncated":"Herlev and Gentofte Hospital \/ Nutricia Inc"},{"orgOrder":0,"company":"Vivatech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Omnia","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Vivatech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivatech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vivatech \/ Undisclosed"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Orange Peel Fermentation","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Sachet","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Ped3CB","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Proteimax Biotechnology Israel LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Pep19","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Proteimax Biotechnology Israel LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proteimax Biotechnology Israel LTD \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Proteimax Biotechnology Israel LTD \/ Undisclosed"},{"orgOrder":0,"company":"Nuritas Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"IRELAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Pepticontrol","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nuritas Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuritas Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nuritas Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"National Health Service, UK","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Peptide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ National Health Service, UK","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ National Health Service, UK"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"PF 05212389","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PF-07976016","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PF-07976016","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PH284","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Microphyt","sponsor":"Texas A&M University","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Phaeosol","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Microphyt","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microphyt \/ Texas A&M University","highestDevelopmentStatusID":"1","companyTruncated":"Microphyt \/ Texas A&M University"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Informapro Srl | Universita degli Studi di Catania","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Phaseolus Vulgaris L. Dry Extract","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSA Institut Biochimique \/ Informapro Srl | Universita degli Studi di Catania","highestDevelopmentStatusID":"1","companyTruncated":"IBSA Institut Biochimique \/ Informapro Srl | Universita degli Studi di Catania"},{"orgOrder":0,"company":"Medical University of South Carolina","sponsor":"Aker BioMarine Human Ingredients AS","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Phospholipid-Bound Omega-3","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Medical University of South Carolina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of South Carolina \/ Aker BioMarine Human Ingredients AS","highestDevelopmentStatusID":"1","companyTruncated":"Medical University of South Carolina \/ Aker BioMarine Human Ingredients AS"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Plant Based Oral Nutritional Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Undisclosed"},{"orgOrder":0,"company":"Brightseed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Plant Derived Phenolics","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Brightseed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brightseed \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Brightseed \/ Undisclosed"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"Raisio Nutrition Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Plant Stanol","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ Raisio Nutrition Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Maastricht University Medical Center \/ Raisio Nutrition Ltd."},{"orgOrder":0,"company":"Canadian Center for Functional Medicine","sponsor":"University of British Columbia | InovoBiologic Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Polyglycoplex","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Canadian Center for Functional Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian Center for Functional Medicine \/ University of British Columbia | InovoBiologic Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Canadian Center for Functional Medicine \/ University of British Columbia | InovoBiologic Inc."},{"orgOrder":0,"company":"Canadian Center for Functional Medicine","sponsor":"University of British Columbia | InovoBiologic Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Polyglycoplex","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Canadian Center for Functional Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian Center for Functional Medicine \/ University of British Columbia | InovoBiologic Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Canadian Center for Functional Medicine \/ University of British Columbia | InovoBiologic Inc."},{"orgOrder":0,"company":"University of Reading","sponsor":"The Norwegian Institute of Food, Fisheries and Aquaculture research (NOFIMA) | National Research Institute for Agriculture, Food and environment (INRAE) | Biotechnology and Biological Sciences Research Council | European Joint Programming Initiative A Hea","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Porridge","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Reading","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Reading \/ The Norwegian Institute of Food, Fisheries and Aquaculture research (NOFIMA) | National Research Institute for Agriculture, Food and environment (INRAE) | Biotechnology and Biological Sciences Research Council | European Joint Programming Initiative A Hea","highestDevelopmentStatusID":"1","companyTruncated":"University of Reading \/ The Norwegian Institute of Food, Fisheries and Aquaculture research (NOFIMA) | National Research Institute for Agriculture, Food and environment (INRAE) | Biotechnology and Biological Sciences Research Council | European Joint Programming Initiative A Hea"},{"orgOrder":0,"company":"ResBiotic Nutrition, Inc.","sponsor":"Able Biolabs, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Postbiotic","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"ResBiotic Nutrition, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ResBiotic Nutrition, Inc. \/ Able Biolabs, LLC","highestDevelopmentStatusID":"1","companyTruncated":"ResBiotic Nutrition, Inc. \/ Able Biolabs, LLC"},{"orgOrder":0,"company":"Joel Puente","sponsor":"Crown Sport Nutrition | Go Fit Spain","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Post-Workout Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Joel Puente","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joel Puente \/ Crown Sport Nutrition | Go Fit Spain","highestDevelopmentStatusID":"1","companyTruncated":"Joel Puente \/ Crown Sport Nutrition | Go Fit Spain"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Potassium Phosphate","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"University of Greenwich","sponsor":"Crown Sport Nutrition | Go Fit Spain","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Pre-Workout Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Greenwich","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Greenwich \/ Crown Sport Nutrition | Go Fit Spain","highestDevelopmentStatusID":"1","companyTruncated":"University of Greenwich \/ Crown Sport Nutrition | Go Fit Spain"},{"orgOrder":0,"company":"Joel Puente","sponsor":"Crown Sport Nutrition | Go Fit Spain","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Pre-Workout Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Joel Puente","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joel Puente \/ Crown Sport Nutrition | Go Fit Spain","highestDevelopmentStatusID":"1","companyTruncated":"Joel Puente \/ Crown Sport Nutrition | Go Fit Spain"},{"orgOrder":0,"company":"Sanni Raju","sponsor":"Ohio State University","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Primavie","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Sanni Raju","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanni Raju \/ Ohio State University","highestDevelopmentStatusID":"1","companyTruncated":"Sanni Raju \/ Ohio State University"},{"orgOrder":0,"company":"TargEDys","sponsor":"Analyze & Realize","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Probiosatys","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"TargEDys","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TargEDys \/ Analyze & Realize","highestDevelopmentStatusID":"1","companyTruncated":"TargEDys \/ Analyze & Realize"},{"orgOrder":0,"company":"Technological Centre of Nutrition and Health, Spain","sponsor":"SILICIUM ESPA\u00d1A LABORATORIOS SLU | Hospital Universitari Sant Joan de Reus | University Rovira i Virgili","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Prod1","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Technological Centre of Nutrition and Health, Spain","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Technological Centre of Nutrition and Health, Spain \/ SILICIUM ESPA\u00d1A LABORATORIOS SLU | Hospital Universitari Sant Joan de Reus | University Rovira i Virgili","highestDevelopmentStatusID":"1","companyTruncated":"Technological Centre of Nutrition and Health, Spain \/ SILICIUM ESPA\u00d1A LABORATORIOS SLU | Hospital Universitari Sant Joan de Reus | University Rovira i Virgili"},{"orgOrder":0,"company":"Waldkrankenhaus Protestant Hospital, Spandau","sponsor":"Humana","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Protein Reduced Alpha-Lactalbumin","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Waldkrankenhaus Protestant Hospital, Spandau","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Waldkrankenhaus Protestant Hospital, Spandau \/ Humana","highestDevelopmentStatusID":"1","companyTruncated":"Waldkrankenhaus Protestant Hospital, Spandau \/ Humana"},{"orgOrder":0,"company":"University of Chile","sponsor":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico, Chile | Royal DSM | Corporaci\u00f3n de Apoyo de la Investigaci\u00f3n Cient\u00edfica en Nutrici\u00f3n","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHILE","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Pufa Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Chile","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Chile \/ Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico, Chile | Royal DSM | Corporaci\u00f3n de Apoyo de la Investigaci\u00f3n Cient\u00edfica en Nutrici\u00f3n","highestDevelopmentStatusID":"1","companyTruncated":"University of Chile \/ Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico, Chile | Royal DSM | Corporaci\u00f3n de Apoyo de la Investigaci\u00f3n Cient\u00edfica en Nutrici\u00f3n"},{"orgOrder":0,"company":"University of Calgary","sponsor":"Alberta Innovates Health Solutions | Alberta Innovates Bio Solutions | Alberta Pulse Growers","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Pulse Fibre","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ Alberta Innovates Health Solutions | Alberta Innovates Bio Solutions | Alberta Pulse Growers","highestDevelopmentStatusID":"1","companyTruncated":"University of Calgary \/ Alberta Innovates Health Solutions | Alberta Innovates Bio Solutions | Alberta Pulse Growers"},{"orgOrder":0,"company":"Greenyn Biotechnology","sponsor":"Taipei Medical University WanFang Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Pumpkin Seed Extract","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Greenyn Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Greenyn Biotechnology \/ Taipei Medical University WanFang Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Greenyn Biotechnology \/ Taipei Medical University WanFang Hospital"},{"orgOrder":0,"company":"Qualia Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Qualia Magnesium Plus","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Qualia Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualia Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Qualia Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz","sponsor":"Alicorp S.A.A.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Quinoa","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz \/ Alicorp S.A.A.","highestDevelopmentStatusID":"1","companyTruncated":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz \/ Alicorp S.A.A."},{"orgOrder":0,"company":"Raynovent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RAY1225","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Raynovent Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raynovent Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Raynovent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Raynovent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RAY1225","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Raynovent Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raynovent Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Raynovent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Raynovent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RAY1225","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Raynovent Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raynovent Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Raynovent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Sanofi | Hospices Civils de Lyon","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"recombinant influenza vaccine","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Sanofi | Hospices Civils de Lyon","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Sanofi | Hospices Civils de Lyon"},{"orgOrder":0,"company":"Golo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Release Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Golo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Golo \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Golo \/ Undisclosed"},{"orgOrder":0,"company":"Golo","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Release Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Golo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Golo \/ KGK Science","highestDevelopmentStatusID":"10","companyTruncated":"Golo \/ KGK Science"},{"orgOrder":0,"company":"University of Rochester","sponsor":"Smartfish AS","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Remune","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Rochester \/ Smartfish AS","highestDevelopmentStatusID":"6","companyTruncated":"University of Rochester \/ Smartfish AS"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Renutryl Booster","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RES-010","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Resalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resalis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Resalis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Sunstone Life Science Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"RES-010","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Resalis Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Resalis Therapeutics \/ Sunstone Life Science Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Resalis Therapeutics \/ Sunstone Life Science Ventures"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"RES-010","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Resalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resalis Therapeutics \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Resalis Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Claris Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"RES-010","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Resalis Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Resalis Therapeutics \/ Claris Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Resalis Therapeutics \/ Claris Ventures"},{"orgOrder":0,"company":"USDA, Western Human Nutrition Research Center","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh | World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Vitamin A Palmitate","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"USDA, Western Human Nutrition Research Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"USDA, Western Human Nutrition Research Center \/ International Centre for Diarrhoeal Disease Research, Bangladesh | World Health Organization","highestDevelopmentStatusID":"1","companyTruncated":"USDA, Western Human Nutrition Research Center \/ International Centre for Diarrhoeal Disease Research, Bangladesh | World Health Organization"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RGT001-075","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RGT001-075","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rejuven Dermaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"RJV001","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rejuven Dermaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rejuven Dermaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rejuven Dermaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"RM-718","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"RM-718","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RO7204239","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RO7795081","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RO7795081","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"RT-114","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"PG-102","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"ProGen","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2024","type":"Partnership","leadProduct":"RT-114","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ ProGen","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ ProGen"},{"orgOrder":0,"company":"International Centre for Diarrhoeal Disease Research, Bangladesh","sponsor":"UNICEF | Nutriset","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BANGLADESH","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Rutf-1","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"International Centre for Diarrhoeal Disease Research, Bangladesh","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ UNICEF | Nutriset","highestDevelopmentStatusID":"9","companyTruncated":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ UNICEF | Nutriset"},{"orgOrder":0,"company":"S1 Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"S1B-509","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"S1 Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"S1 Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"S1 Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"S309309","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"S309309","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"S309309","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Rutgers University","sponsor":"OmniActive Health Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Salacia Chinensis","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Rutgers University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rutgers University \/ OmniActive Health Technologies","highestDevelopmentStatusID":"1","companyTruncated":"Rutgers University \/ OmniActive Health Technologies"},{"orgOrder":0,"company":"Mibelle AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Santa Herba","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Mibelle AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mibelle AG \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Mibelle AG \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SAR441255","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sable Therapeutics","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"SBL-001","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Sable Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sable Therapeutics \/ Columbia University","highestDevelopmentStatusID":"4","companyTruncated":"Sable Therapeutics \/ Columbia University"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Selenious Acid","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR20004","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Anagram Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"SNSP003","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cystic Fibrosis Foundation \/ Synspira Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Cystic Fibrosis Foundation \/ Synspira Therapeutics"},{"orgOrder":0,"company":"Anagram Therapeutics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Funding","leadProduct":"SNSP003","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Anagram Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Anagram Therapeutics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Anagram Therapeutics \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Bionov","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Sodb Dimpless","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Bionov","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bionov \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bionov \/ Undisclosed"},{"orgOrder":0,"company":"Goldman, Butterwick, Fitzpatrick and Groff","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sodium Deoxycholate","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Goldman, Butterwick, Fitzpatrick and Groff","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Goldman, Butterwick, Fitzpatrick and Groff \/ Allergan","highestDevelopmentStatusID":"11","companyTruncated":"Goldman, Butterwick, Fitzpatrick and Groff \/ Allergan"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Sondalis Hp","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Imperial College London | Imperial Clinical Trials Unit","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Spice Blend","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Imperial College London | Imperial Clinical Trials Unit","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Imperial College London | Imperial Clinical Trials Unit"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SRK-439","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scholar Rock \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Scholar Rock \/ Undisclosed"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SRK-439","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scholar Rock \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Scholar Rock \/ Undisclosed"},{"orgOrder":0,"company":"University of Manchester","sponsor":"Cargill","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Stevioside A3","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Manchester","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Manchester \/ Cargill","highestDevelopmentStatusID":"1","companyTruncated":"University of Manchester \/ Cargill"},{"orgOrder":0,"company":"Aymes International Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Stockholm","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Aymes International Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aymes International Limited \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Aymes International Limited \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Strath AG","sponsor":"Zentrum f\u00fcr Adipositas- und Stoffwechselmedizin Winterthur GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Strath Kr\u00e4uterhefe","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Bio-Strath AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Strath AG \/ Zentrum f\u00fcr Adipositas- und Stoffwechselmedizin Winterthur GmbH","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Strath AG \/ Zentrum f\u00fcr Adipositas- und Stoffwechselmedizin Winterthur GmbH"},{"orgOrder":0,"company":"Indonesia University","sponsor":"Dexa Medica","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDONESIA","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Striatin","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Indonesia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indonesia University \/ Dexa Medica","highestDevelopmentStatusID":"1","companyTruncated":"Indonesia University \/ Dexa Medica"},{"orgOrder":0,"company":"Universitas Sriwijaya","sponsor":"Dexa Medica","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Striatin Extract","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Universitas Sriwijaya","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitas Sriwijaya \/ Dexa Medica","highestDevelopmentStatusID":"10","companyTruncated":"Universitas Sriwijaya \/ Dexa Medica"},{"orgOrder":0,"company":"Antria","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Stromal Vascular Fraction Containing Adipose Derived Stem Cell","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Antria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antria \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antria \/ Undisclosed"},{"orgOrder":0,"company":"M\u00aa Jes\u00fas Periago","sponsor":"Ingredalia Company | Spanish National Research Council","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Sulforaphan Smart","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"M\u00aa Jes\u00fas Periago","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Pill","sponsorNew":"M\u00aa Jes\u00fas Periago \/ Ingredalia Company | Spanish National Research Council","highestDevelopmentStatusID":"6","companyTruncated":"M\u00aa Jes\u00fas Periago \/ Ingredalia Company | Spanish National Research Council"},{"orgOrder":0,"company":"Scotmann Pharmaceuticals","sponsor":"Rawalpindi Medical College","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"PAKISTAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Sunnyd Stat","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scotmann Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Scotmann Pharmaceuticals \/ Rawalpindi Medical College","highestDevelopmentStatusID":"8","companyTruncated":"Scotmann Pharmaceuticals \/ Rawalpindi Medical College"},{"orgOrder":0,"company":"CSPC Baike","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SYH9017","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CSPC Baike","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC Baike \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSPC Baike \/ Undisclosed"},{"orgOrder":0,"company":"Texas Christian University","sponsor":"Pendulum Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Synbiotic","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Texas Christian University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Texas Christian University \/ Pendulum Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Texas Christian University \/ Pendulum Therapeutics"},{"orgOrder":0,"company":"Integrative Health Technologies, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Synephrine","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Integrative Health Technologies, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integrative Health Technologies, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Integrative Health Technologies, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Sciwind Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"T2026","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sciwind Biosciences \/ Sciwind Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sciwind Biosciences \/ Sciwind Biosciences"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"TCI378","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Vegenat, S.A.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"T-Diet","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Vegenat, S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vegenat, S.A. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vegenat, S.A. \/ Undisclosed"},{"orgOrder":0,"company":"Immunwork","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TE-8105","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Immunwork","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunwork \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunwork \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Baike","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TG103","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"CSPC Baike","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC Baike \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC Baike \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Baike","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TG103","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"CSPC Baike","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC Baike \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC Baike \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Baike","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TG103","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"CSPC Baike","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Baike \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC Baike \/ Undisclosed"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"THDBH120","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonghua Dongbao Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"THDBH120","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonghua Dongbao Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MetaProteomics LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"THIAA","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"MetaProteomics LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MetaProteomics LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"MetaProteomics LLC \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Thiamine Hydrochloride","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Neurobiogen","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Neurobiogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurobiogen \/ Scilex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Neurobiogen \/ Scilex Pharmaceuticals"},{"orgOrder":0,"company":"Neurobiogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Neurobiogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurobiogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurobiogen \/ Undisclosed"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scilex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"IPMC","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scilex Pharmaceuticals \/ IPMC","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ IPMC"},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TPT0701","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Tetra Pharm Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetra Pharm Technologies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Tetra Pharm Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Pharmanex","sponsor":"Utah State University","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Tr90 Eating Plan","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Pharmanex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmanex \/ Utah State University","highestDevelopmentStatusID":"1","companyTruncated":"Pharmanex \/ Utah State University"},{"orgOrder":0,"company":"Texas A&M University","sponsor":"Curves International","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Trutol Glucose","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Texas A&M University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Texas A&M University \/ Curves International","highestDevelopmentStatusID":"1","companyTruncated":"Texas A&M University \/ Curves International"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TT-02332","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransThera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"TransThera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Utopia Therapeutics","sponsor":"Whale Tank","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Vaccine","year":"2025","type":"Financing","leadProduct":"UT009","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Utopia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Utopia Therapeutics \/ Whale Tank","highestDevelopmentStatusID":"4","companyTruncated":"Utopia Therapeutics \/ Whale Tank"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Johns Hopkins University | Rutgers University | Inova Health Care Services","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Vaginal Seeding","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Johns Hopkins University | Rutgers University | Inova Health Care Services","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Johns Hopkins University | Rutgers University | Inova Health Care Services"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Centre d'Investigation Clinique INSERM 501, Clermont-Ferrand, France | Laboratoire des Adaptations M\u00e9taboliques \u00e0 l'Exercice en conditions Physiologiques et Pathologiques","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Valedia","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Centre d'Investigation Clinique INSERM 501, Clermont-Ferrand, France | Laboratoire des Adaptations M\u00e9taboliques \u00e0 l'Exercice en conditions Physiologiques et Pathologiques","highestDevelopmentStatusID":"6","companyTruncated":"Valbiotis \/ Centre d'Investigation Clinique INSERM 501, Clermont-Ferrand, France | Laboratoire des Adaptations M\u00e9taboliques \u00e0 l'Exercice en conditions Physiologiques et Pathologiques"},{"orgOrder":0,"company":"Vincentage Pharma","sponsor":"Corxel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"VCT220","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Vincentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vincentage Pharma \/ Corxel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Vincentage Pharma \/ Corxel Pharmaceuticals"},{"orgOrder":0,"company":"Vincentage Pharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VCT220","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Vincentage Pharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vincentage Pharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vincentage Pharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Vincentage Pharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VCT220","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Vincentage Pharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vincentage Pharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vincentage Pharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Vincentage Pharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VCT220","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Vincentage Pharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vincentage Pharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vincentage Pharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Vincentage Pharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VCT220","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Vincentage Pharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vincentage Pharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vincentage Pharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Fytexia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Verum900","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Fytexia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fytexia \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Fytexia \/ Undisclosed"},{"orgOrder":0,"company":"King's College London","sponsor":"Lighterlife Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Very Low Calorie Diet","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"King's College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"King's College London \/ Lighterlife Ltd","highestDevelopmentStatusID":"1","companyTruncated":"King's College London \/ Lighterlife Ltd"},{"orgOrder":0,"company":"Christiana Care Health Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Very Low Calorie Diet","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Christiana Care Health Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Christiana Care Health Services \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Christiana Care Health Services \/ Undisclosed"},{"orgOrder":0,"company":"InnoNext Sarl","sponsor":"University of Health and Allied Sciences | Haleon","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Vitamin","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"InnoNext Sarl","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Powder","sponsorNew":"InnoNext Sarl \/ University of Health and Allied Sciences | Haleon","highestDevelopmentStatusID":"10","companyTruncated":"InnoNext Sarl \/ University of Health and Allied Sciences | Haleon"},{"orgOrder":0,"company":"MDCPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Vitamin Complex","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"MDCPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MDCPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MDCPharma \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Wehand-Bio Pharmaceutical","sponsor":"Peking University First Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Wh006","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Beijing Wehand-Bio Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Wehand-Bio Pharmaceutical \/ Peking University First Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Wehand-Bio Pharmaceutical \/ Peking University First Hospital"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Arla Foods | Nupo A\/S, Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Whey Protein","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Arla Foods | Nupo A\/S, Denmark","highestDevelopmentStatusID":"1","companyTruncated":"University of Copenhagen \/ Arla Foods | Nupo A\/S, Denmark"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Slagelse Hospital | Arla Foods","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Whey Protein","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Slagelse Hospital | Arla Foods","highestDevelopmentStatusID":"1","companyTruncated":"University of Copenhagen \/ Slagelse Hospital | Arla Foods"},{"orgOrder":0,"company":"NIZO Food Research","sponsor":"FrieslandCampina","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Whey Protein","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"NIZO Food Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIZO Food Research \/ FrieslandCampina","highestDevelopmentStatusID":"1","companyTruncated":"NIZO Food Research \/ FrieslandCampina"},{"orgOrder":0,"company":"University of Nottingham","sponsor":"Mars","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Whey Protein","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Nottingham","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Nottingham \/ Mars","highestDevelopmentStatusID":"1","companyTruncated":"University of Nottingham \/ Mars"},{"orgOrder":0,"company":"University of Kansas","sponsor":"Dairy Management Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Whey Protein","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Kansas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Kansas \/ Dairy Management Inc.","highestDevelopmentStatusID":"1","companyTruncated":"University of Kansas \/ Dairy Management Inc."},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Whole Grain","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"WM Formula","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"10xbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"XB-101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"10xbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"10xbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"10xbio \/ Undisclosed"},{"orgOrder":0,"company":"10xbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"XB-101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"10xbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"10xbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"10xbio \/ Undisclosed"},{"orgOrder":0,"company":"Xeno Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"XEN-101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Xeno Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xeno Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xeno Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Xeno Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"XEN-101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Xeno Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xeno Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xeno Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"YSOPIA Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Xla1","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"YSOPIA Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YSOPIA Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"YSOPIA Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Faidon Magkos","sponsor":"Arla Food for Health | University of Aarhus | M\u00e6lkeafgiftsfonden | University of Copenhagen, Department of Biology","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Yoghurt","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Faidon Magkos","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faidon Magkos \/ Arla Food for Health | University of Aarhus | M\u00e6lkeafgiftsfonden | University of Copenhagen, Department of Biology","highestDevelopmentStatusID":"1","companyTruncated":"Faidon Magkos \/ Arla Food for Health | University of Aarhus | M\u00e6lkeafgiftsfonden | University of Copenhagen, Department of Biology"},{"orgOrder":0,"company":"Yaopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"YP05002","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Yaopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yaopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Yaopharma \/ Undisclosed"},{"orgOrder":0,"company":"Vitaflo International, Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Zestivits","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Vitaflo International, Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vitaflo International, Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vitaflo International, Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Lesaffre International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Zinc-Enriched Yeast","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Lesaffre International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lesaffre International \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lesaffre International \/ Undisclosed"},{"orgOrder":0,"company":"Beijing QL Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZT002","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Beijing QL Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing QL Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing QL Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Beijing QL Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ZT002","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Beijing QL Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing QL Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing QL Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"ZYT1","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"BrightGene Bio-Medical Technology Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"BrightGene Bio-Medical Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BrightGene Bio-Medical Technology Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BrightGene Bio-Medical Technology Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Trinity Health of New England","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Trinity Health of New England","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trinity Health of New England \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Trinity Health of New England \/ Undisclosed"},{"orgOrder":0,"company":"McLaren Regional Medical Center","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"McLaren Regional Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McLaren Regional Medical Center \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"McLaren Regional Medical Center \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"University of Indonesia","sponsor":"Interbat Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDONESIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cobamamide","moa":"Vitamin B12-dependent enzyme","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Indonesia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Indonesia \/ Interbat Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Indonesia \/ Interbat Pharmaceuticals"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BRAZIL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Pyridoxine Hydrochloride","moa":"Vitamin B6 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Wageningen University","sponsor":"Top Institute Food and Nutrition | Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Wageningen University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wageningen University \/ Top Institute Food and Nutrition | Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Wageningen University \/ Top Institute Food and Nutrition | Royal DSM"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Faes Farma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Faes Farma \/ Undisclosed"},{"orgOrder":0,"company":"Kwang Dong Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Kwang Dong Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kwang Dong Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kwang Dong Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Kwang Dong Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Kwang Dong Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kwang Dong Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kwang Dong Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Semmelweis University","sponsor":"Pharma Patent","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"HUNGARY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Semmelweis University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Semmelweis University \/ Pharma Patent","highestDevelopmentStatusID":"10","companyTruncated":"Semmelweis University \/ Pharma Patent"},{"orgOrder":0,"company":"Semmelweis University","sponsor":"Pharma Patent","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"HUNGARY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Semmelweis University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Semmelweis University \/ Pharma Patent","highestDevelopmentStatusID":"10","companyTruncated":"Semmelweis University \/ Pharma Patent"},{"orgOrder":0,"company":"Children's Memorial Health Institute, Poland","sponsor":"Nutropharma Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"POLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Children's Memorial Health Institute, Poland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Memorial Health Institute, Poland \/ Nutropharma Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Children's Memorial Health Institute, Poland \/ Nutropharma Ltd."},{"orgOrder":0,"company":"Children's Hospital of Eastern Ontario","sponsor":"Canadian Institutes of Health Research | EURO-PHARM INTERNATIONAL CANADA INC | Canadian Critical Care Trials Group","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Children's Hospital of Eastern Ontario","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Eastern Ontario \/ Canadian Institutes of Health Research | EURO-PHARM INTERNATIONAL CANADA INC | Canadian Critical Care Trials Group","highestDevelopmentStatusID":"10","companyTruncated":"Children's Hospital of Eastern Ontario \/ Canadian Institutes of Health Research | EURO-PHARM INTERNATIONAL CANADA INC | Canadian Critical Care Trials Group"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Physician Services Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Physician Services Incorporated","highestDevelopmentStatusID":"1","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Physician Services Incorporated"},{"orgOrder":0,"company":"Tufts University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Tufts University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tufts University \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Tufts University \/ Pfizer Inc"},{"orgOrder":0,"company":"Tufts University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Tufts University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tufts University \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Tufts University \/ Pfizer Inc"},{"orgOrder":0,"company":"Prisma Health-Midlands","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Prisma Health-Midlands","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prisma Health-Midlands \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Prisma Health-Midlands \/ Undisclosed"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"University of Wisconsin, Madison \/ Merck & Co"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Bio-Tech Pharmacal, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Bio-Tech Pharmacal, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Massachusetts General Hospital \/ Bio-Tech Pharmacal, Inc."},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Bio-Tech Pharmacal, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Bio-Tech Pharmacal, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Massachusetts General Hospital \/ Bio-Tech Pharmacal, Inc."},{"orgOrder":0,"company":"OPKO Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"CTAP101","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OPKO Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OPKO Health \/ Undisclosed"},{"orgOrder":0,"company":"Cook County Health","sponsor":"Rush University","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Cook County Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cook County Health \/ Rush University","highestDevelopmentStatusID":"11","companyTruncated":"Cook County Health \/ Rush University"},{"orgOrder":0,"company":"Albany College of Pharmacy and Health Sciences","sponsor":"VA Office of Research and Development | Hortense & Louis Rubin Dialysis Center | Satellite Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Albany College of Pharmacy and Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albany College of Pharmacy and Health Sciences \/ VA Office of Research and Development | Hortense & Louis Rubin Dialysis Center | Satellite Healthcare","highestDevelopmentStatusID":"11","companyTruncated":"Albany College of Pharmacy and Health Sciences \/ VA Office of Research and Development | Hortense & Louis Rubin Dialysis Center | Satellite Healthcare"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Aga Khan University","sponsor":"John Snow, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"PAKISTAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Aga Khan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aga Khan University \/ John Snow, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Aga Khan University \/ John Snow, Inc."},{"orgOrder":0,"company":"Nutrition Institute, Slovenia","sponsor":"VIST | Slovenian Research Agency | Valens Int. d.o.o., Slovenija","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SLOVENIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nutrition Institute, Slovenia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrition Institute, Slovenia \/ VIST | Slovenian Research Agency | Valens Int. d.o.o., Slovenija","highestDevelopmentStatusID":"1","companyTruncated":"Nutrition Institute, Slovenia \/ VIST | Slovenian Research Agency | Valens Int. d.o.o., Slovenija"},{"orgOrder":0,"company":"University of Ulster","sponsor":"Queen Margaret University, Nutrition and Biological Sciences, Musselburgh, Scotland, UK | Better You ltd., Unit 24 Shortwood Court, Shortwood Business Park, Dearne Valley Parkway, Barnsley, S74 9LH, Registered Company No: 05541287","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Ulster","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Ulster \/ Queen Margaret University, Nutrition and Biological Sciences, Musselburgh, Scotland, UK | Better You ltd., Unit 24 Shortwood Court, Shortwood Business Park, Dearne Valley Parkway, Barnsley, S74 9LH, Registered Company No: 05541287","highestDevelopmentStatusID":"1","companyTruncated":"University of Ulster \/ Queen Margaret University, Nutrition and Biological Sciences, Musselburgh, Scotland, UK | Better You ltd., Unit 24 Shortwood Court, Shortwood Business Park, Dearne Valley Parkway, Barnsley, S74 9LH, Registered Company No: 05541287"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"QATAR","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Instituto Nacional de Salud Publica, Mexico","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"MEXICO","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Instituto Nacional de Salud Publica, Mexico","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto Nacional de Salud Publica, Mexico \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Instituto Nacional de Salud Publica, Mexico \/ Royal DSM"},{"orgOrder":0,"company":"Instituto Nacional de Salud Publica, Mexico","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"MEXICO","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Instituto Nacional de Salud Publica, Mexico","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto Nacional de Salud Publica, Mexico \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Instituto Nacional de Salud Publica, Mexico \/ Royal DSM"},{"orgOrder":0,"company":"Fundaci\u00f3n Cardiovascular de Colombia","sponsor":"Universidad Industrial de Santander | Farma de Colombia","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"COLOMBIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Fundaci\u00f3n Cardiovascular de Colombia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundaci\u00f3n Cardiovascular de Colombia \/ Universidad Industrial de Santander | Farma de Colombia","highestDevelopmentStatusID":"1","companyTruncated":"Fundaci\u00f3n Cardiovascular de Colombia \/ Universidad Industrial de Santander | Farma de Colombia"},{"orgOrder":0,"company":"University of Eastern Finland","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FINLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"University of Eastern Finland","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Pill","sponsorNew":"University of Eastern Finland \/ Royal DSM","highestDevelopmentStatusID":"6","companyTruncated":"University of Eastern Finland \/ Royal DSM"},{"orgOrder":0,"company":"Queen's University, Belfast","sponsor":"Health and Social Care Research and Development , Northern Ireland | Royal Victoria Hospital, Belfast | Northern Ireland Chest Heart and Stroke","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Queen's University, Belfast","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Queen's University, Belfast \/ Health and Social Care Research and Development , Northern Ireland | Royal Victoria Hospital, Belfast | Northern Ireland Chest Heart and Stroke","highestDevelopmentStatusID":"1","companyTruncated":"Queen's University, Belfast \/ Health and Social Care Research and Development , Northern Ireland | Royal Victoria Hospital, Belfast | Northern Ireland Chest Heart and Stroke"},{"orgOrder":0,"company":"Hayat Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JORDAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Hayat Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hayat Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hayat Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Inspired Life Medical, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Inspired Life Medical, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inspired Life Medical, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Inspired Life Medical, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Cure Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cure Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cure Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Factors Group of Nutritional Companies Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Factors Group of Nutritional Companies Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Factors Group of Nutritional Companies Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Factors Group of Nutritional Companies Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Vitamin K1","moa":"Vitamin K","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Vitamin K1","moa":"Vitamin K","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Deuterium Oxide","moa":"Water","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Liquid","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"JiKang Therapeutics","sponsor":"BioAge Labs","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"JiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"JiKang Therapeutics \/ BioAge Labs","highestDevelopmentStatusID":"4","companyTruncated":"JiKang Therapeutics \/ BioAge Labs"},{"orgOrder":0,"company":"Shanghai Minwei Biotechnology Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Shanghai Minwei Biotechnology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Minwei Biotechnology Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Minwei Biotechnology Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Kunshan First People's Hospital Affiliated to Jiangsu University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Kunshan First People's Hospital Affiliated to Jiangsu University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kunshan First People's Hospital Affiliated to Jiangsu University \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kunshan First People's Hospital Affiliated to Jiangsu University \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Precision Health Food Technology Co. Ltd.,","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Shenzhen Precision Health Food Technology Co. Ltd.,","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Precision Health Food Technology Co. Ltd., \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen Precision Health Food Technology Co. Ltd., \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Precision Health Food Technology Co. Ltd.,","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Shenzhen Precision Health Food Technology Co. Ltd.,","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Precision Health Food Technology Co. Ltd., \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen Precision Health Food Technology Co. Ltd., \/ Undisclosed"},{"orgOrder":0,"company":"Aga Khan University","sponsor":"United Nations World Food Programme (WFP) | People's Primary Healthcare Initiative, Sindh","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"PAKISTAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Aga Khan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aga Khan University \/ United Nations World Food Programme (WFP) | People's Primary Healthcare Initiative, Sindh","highestDevelopmentStatusID":"1","companyTruncated":"Aga Khan University \/ United Nations World Food Programme (WFP) | People's Primary Healthcare Initiative, Sindh"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PeptiDream \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"PeptiDream \/ Undisclosed"},{"orgOrder":0,"company":"Dx&Vx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Dx&Vx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dx&Vx \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Dx&Vx \/ Undisclosed"},{"orgOrder":0,"company":"VedTechBio","sponsor":"RenaissThera","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"VedTechBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VedTechBio \/ RenaissThera","highestDevelopmentStatusID":"3","companyTruncated":"VedTechBio \/ RenaissThera"},{"orgOrder":0,"company":"Glycom A\/S","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Glycom A\/S","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycom A\/S \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Glycom A\/S \/ Undisclosed"},{"orgOrder":0,"company":"Danisco France SAS","sponsor":"Eurofins CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Danisco France SAS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco France SAS \/ Eurofins CDMO","highestDevelopmentStatusID":"1","companyTruncated":"Danisco France SAS \/ Eurofins CDMO"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Undisclosed"},{"orgOrder":0,"company":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz","sponsor":"Adventia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz \/ Adventia Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz \/ Adventia Pharma"},{"orgOrder":0,"company":"West German Center of Diabetes and Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"West German Center of Diabetes and Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"West German Center of Diabetes and Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"West German Center of Diabetes and Health \/ Undisclosed"},{"orgOrder":0,"company":"Camurus","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Camurus","amount2":0.87,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.87,"dosageForm":"Injection","sponsorNew":"Camurus \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Camurus \/ Eli Lilly"},{"orgOrder":0,"company":"Iconovo","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Iconovo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Spray","sponsorNew":"Iconovo \/ Lonza Group","highestDevelopmentStatusID":"1","companyTruncated":"Iconovo \/ Lonza Group"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Ascendis Pharma","amount2":0.28999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.28999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Ascendis Pharma \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Ascendis Pharma \/ Novo Nordisk"},{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"HAYA Therapeutics","amount2":1,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"HAYA Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"HAYA Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Oranda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"IRELAND","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Oranda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oranda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Endevica Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orbit Discovery \/ Endevica Bio","highestDevelopmentStatusID":"2","companyTruncated":"Orbit Discovery \/ Endevica Bio"},{"orgOrder":0,"company":"Eracal Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Eracal Therapeutics","amount2":0.26000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.26000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Eracal Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Eracal Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Eracal Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Eracal Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eracal Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Eracal Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Evotec","sponsor":"Inserm","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Inserm","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Inserm"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Driehaus Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Confo Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Confo Therapeutics \/ Driehaus Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Confo Therapeutics \/ Driehaus Capital Management"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Clinical Nutrition Research Center, Illinois Institute of Technology","sponsor":"California Strawberry Commission","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Clinical Nutrition Research Center, Illinois Institute of Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ California Strawberry Commission","highestDevelopmentStatusID":"1","companyTruncated":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ California Strawberry Commission"},{"orgOrder":0,"company":"Clinical Nutrition Research Center, Illinois Institute of Technology","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Clinical Nutrition Research Center, Illinois Institute of Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ GSK"},{"orgOrder":0,"company":"Clinical Nutrition Research Center, Illinois Institute of Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Clinical Nutrition Research Center, Illinois Institute of Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ Undisclosed"},{"orgOrder":0,"company":"Clinical Nutrition Research Center, Illinois Institute of Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Clinical Nutrition Research Center, Illinois Institute of Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ Undisclosed"},{"orgOrder":0,"company":"Clinical Nutrition Research Center, Illinois Institute of Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Clinical Nutrition Research Center, Illinois Institute of Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ Undisclosed"},{"orgOrder":0,"company":"Laval University","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laval University \/ Lallemand Health Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Laval University \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"Western University, Canada","sponsor":"Nutrigenomix Inc. | East Elgin Family Health Team | Canadian Transplant Association","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Western University, Canada","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Western University, Canada \/ Nutrigenomix Inc. | East Elgin Family Health Team | Canadian Transplant Association","highestDevelopmentStatusID":"1","companyTruncated":"Western University, Canada \/ Nutrigenomix Inc. | East Elgin Family Health Team | Canadian Transplant Association"},{"orgOrder":0,"company":"Wuqu' Kawoq, Maya Health Alliance","sponsor":"Universidad del Valle, Guatemala | Grand Challenges Canada","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GUATEMALA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Wuqu' Kawoq, Maya Health Alliance","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wuqu' Kawoq, Maya Health Alliance \/ Universidad del Valle, Guatemala | Grand Challenges Canada","highestDevelopmentStatusID":"1","companyTruncated":"Wuqu' Kawoq, Maya Health Alliance \/ Universidad del Valle, Guatemala | Grand Challenges Canada"},{"orgOrder":0,"company":"Wuqu' Kawoq, Maya Health Alliance","sponsor":"Academy of Nutrition and Dietetics","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GUATEMALA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Wuqu' Kawoq, Maya Health Alliance","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wuqu' Kawoq, Maya Health Alliance \/ Academy of Nutrition and Dietetics","highestDevelopmentStatusID":"1","companyTruncated":"Wuqu' Kawoq, Maya Health Alliance \/ Academy of Nutrition and Dietetics"},{"orgOrder":0,"company":"SixPeaks Bio","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"SixPeaks Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"SixPeaks Bio \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"SixPeaks Bio \/ AstraZeneca"},{"orgOrder":0,"company":"SixPeaks Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"SixPeaks Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"SixPeaks Bio \/ Versant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"SixPeaks Bio \/ Versant Ventures"},{"orgOrder":0,"company":"Ampersand Biomedicines","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Ampersand Biomedicines","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Ampersand Biomedicines \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Ampersand Biomedicines \/ Flagship Pioneering"},{"orgOrder":0,"company":"Universidad Autonoma de Queretaro","sponsor":"NUCITEC S.A. de C.V.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"MEXICO","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Universidad Autonoma de Queretaro","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad Autonoma de Queretaro \/ NUCITEC S.A. de C.V.","highestDevelopmentStatusID":"1","companyTruncated":"Universidad Autonoma de Queretaro \/ NUCITEC S.A. de C.V."},{"orgOrder":0,"company":"Nature's Sunshine Products, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nature's Sunshine Products, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nature's Sunshine Products, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nature's Sunshine Products, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Metsera","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Metsera","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.28999999999999998,"dosageForm":"Injection","sponsorNew":"Metsera \/ Arch Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Metsera \/ Arch Ventures"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Metaphore Biotechnologies","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Metaphore Biotechnologies","amount2":0.59999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.59999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Metaphore Biotechnologies \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Metaphore Biotechnologies \/ Novo Nordisk"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Omega Therapeutics","amount2":0.53000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.53000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Omega Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Omega Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"ProFound Therapeutics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"ProFound Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProFound Therapeutics \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"ProFound Therapeutics \/ Flagship Pioneering"},{"orgOrder":0,"company":"Kallyope","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kallyope \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Kallyope \/ Novo Nordisk"},{"orgOrder":0,"company":"NIMIUM Therapeutics","sponsor":"Paraza Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"NIMIUM Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIMIUM Therapeutics \/ Paraza Pharma","highestDevelopmentStatusID":"4","companyTruncated":"NIMIUM Therapeutics \/ Paraza Pharma"},{"orgOrder":0,"company":"Senda Biosciences","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Senda Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senda Biosciences \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"4","companyTruncated":"Senda Biosciences \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lumen Bioscience \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Lumen Bioscience \/ Novo Nordisk"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Korro Bio","amount2":0.53000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.53000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Korro Bio \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Korro Bio \/ Novo Nordisk"},{"orgOrder":0,"company":"Ampersand Biosciences","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Ampersand Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ampersand Biosciences \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Ampersand Biosciences \/ Flagship Pioneering"},{"orgOrder":0,"company":"Deep Apple Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Deep Apple Therapeutics","amount2":0.81000000000000005,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.81000000000000005,"dosageForm":"Undisclosed","sponsorNew":"Deep Apple Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Deep Apple Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Deep Apple Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Deep Apple Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Deep Apple Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"3","companyTruncated":"Deep Apple Therapeutics \/ Apple Tree Partners"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Regeneron Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Septerna","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Septerna","amount2":2.2000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.2000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Septerna \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Septerna \/ Novo Nordisk"},{"orgOrder":0,"company":"Cronos Group","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Cronos Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cronos Group \/ Ginkgo Bioworks","highestDevelopmentStatusID":"1","companyTruncated":"Cronos Group \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbour BioMed \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Harbour BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Valo Health","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Valo Health","amount2":4.79,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":4.79,"dosageForm":"Undisclosed","sponsorNew":"Valo Health \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Valo Health \/ Novo Nordisk"},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Juvena Therapeutics","amount2":0.65000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.65000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Juvena Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Juvena Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Boxcar Pmj","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Immuneering Corporation","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Boxcar Pmj","highestDevelopmentStatusID":"1","companyTruncated":"Immuneering Corporation \/ Boxcar Pmj"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Silo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Silo Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Silo Pharma"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"US Department of Veterans Affairs","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"GFR Alpha-1","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hoth Therapeutics \/ US Department of Veterans Affairs","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ US Department of Veterans Affairs"},{"orgOrder":0,"company":"Replicate Bioscience","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Replicate Bioscience","amount2":0.55000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.55000000000000004,"dosageForm":"Undisclosed","sponsorNew":"Replicate Bioscience \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Replicate Bioscience \/ Novo Nordisk"},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Superluminal Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Superluminal Medicines \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Superluminal Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Remedium Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Remedium Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedium Bio \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Remedium Bio \/ Eli Lilly"},{"orgOrder":0,"company":"D'Or Institute for Research and Education","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BRAZIL","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"D'Or Institute for Research and Education","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"D'Or Institute for Research and Education \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"1","companyTruncated":"D'Or Institute for Research and Education \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Novo Nordisk","amount2":0.51000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.51000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"HitGen","sponsor":"BioAge Labs","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"BGE-102","moa":"NLRP3","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HitGen \/ BioAge Labs","highestDevelopmentStatusID":"6","companyTruncated":"HitGen \/ BioAge Labs"},{"orgOrder":0,"company":"Cantoni Therapeutics","sponsor":"Brabant Development Agency","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"NNMT","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Cantoni Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cantoni Therapeutics \/ Brabant Development Agency","highestDevelopmentStatusID":"4","companyTruncated":"Cantoni Therapeutics \/ Brabant Development Agency"},{"orgOrder":0,"company":"Metsera","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"MET-097","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":4.9000000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":4.9000000000000004,"dosageForm":"Injection","sponsorNew":"Metsera \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Pfizer Inc"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"RN3161","moa":"INHBE","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Rona Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rona Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Rona Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Bofanglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LY4064912","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bivamelagon","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"IBI3032","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"BrightGene Bio-Medical Technology Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BGM0504","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BrightGene Bio-Medical Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BrightGene Bio-Medical Technology Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BrightGene Bio-Medical Technology Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"MetaFines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ASCA101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"MetaFines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"MetaFines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MetaFines \/ Undisclosed"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aleniglipron","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Structure Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rivus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rivus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"IBI3032","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"The United Bio-Technology (Hengqin) Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"UBT251","moa":"GLP-1|GIP|Glucagon receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"The United Bio-Technology (Hengqin) Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"The United Bio-Technology (Hengqin) Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The United Bio-Technology (Hengqin) Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Beijing QL Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"ZT003","moa":"FGF21R | GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Beijing QL Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing QL Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beijing QL Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NNC0662-0419","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aardvark Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aardvark Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"R.F. Lafferty","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"ART27.13","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artelo Biosciences \/ R.F. Lafferty","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ R.F. Lafferty"},{"orgOrder":0,"company":"SKNY Pharmaceuticals","sponsor":"Mira Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"SKNY-1","moa":"CB1\/CB2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"SKNY Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SKNY Pharmaceuticals \/ Mira Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"SKNY Pharmaceuticals \/ Mira Pharmaceuticals"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Confo Therapeutics \/ Flanders Innovation & Entrepreneurship","highestDevelopmentStatusID":"4","companyTruncated":"Confo Therapeutics \/ Flanders Innovation & Entrepreneurship"},{"orgOrder":0,"company":"Shanghai Xitaili Biomedicine Technology co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"XTL6001","moa":"GCGR | GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Shanghai Xitaili Biomedicine Technology co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Xitaili Biomedicine Technology co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Xitaili Biomedicine Technology co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HM15275","moa":"GLP-1R\/GIPR\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nag Food Supplement Trading LLC","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.A.E","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Collagen","moa":"Collagen hydrolysis","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nag Food Supplement Trading LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nag Food Supplement Trading LLC \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Nag Food Supplement Trading LLC \/ Citruslabs"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Reddy's Laboratories

                            India
                            CPhI WW Frankfurt
                            Booth #9.1B48
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr Reddy’s Labs Gets Nod to Study Popular Weight Loss Medication

                            Details : Semaglutide is a GLP-1 receptor agonist, which is being investigated in Phase 3 for the treatment of weight loss type 2 diabetes and chronic kidney disease.

                            Product Name : Semaglutide-Generic

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            October 19, 2023

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dr. Reddy's Laboratories

                            India
                            CPhI WW Frankfurt
                            Booth #9.1B48
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr Reddy's Gears up for Weight Loss Drug Study

                            Details : subcutaneous semaglutide is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults.

                            Product Name : Semaglutide-Generic

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            October 18, 2023

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Ecnoglutide,Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Sponsor : Sciwind Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sciwind Biosciences Acquires Global, Exclusive Rights to Develop and Commercialize Sanofi's GIP Receptor Agoni...

                            Details : In the terms of the agreement, Sanofi granted exclusive worldwide rights to Sciwind to develop, manufacture and commercialize Sanofi's GIP receptor agonists including XW003, for all applicable indications.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            November 30, 2021

                            Lead Product(s) : Ecnoglutide,Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Sponsor : Sciwind Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : SAR441255

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to O...

                            Details : SAR441255 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Overweight.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 20, 2020

                            Lead Product(s) : SAR441255

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Allergan Aesthetics

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deoxycholic Acid

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

                            Details : Deoxycholic acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Submental Fullness.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 16, 2014

                            Lead Product(s) : Deoxycholic Acid

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Allergan Aesthetics

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deoxycholic Acid

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

                            Details : Deoxycholic acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Submental Fullness.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 10, 2014

                            Lead Product(s) : Deoxycholic Acid

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Allergan Aesthetics

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deoxycholic Acid

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subj...

                            Details : Deoxycholic acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Submental Fullness.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 25, 2014

                            Lead Product(s) : Deoxycholic Acid

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Allergan Aesthetics

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deoxycholic Acid

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

                            Details : Deoxycholic acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Submental Fullness.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 14, 2014

                            Lead Product(s) : Deoxycholic Acid

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Allergan Aesthetics

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deoxycholic Acid

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Patient Experience Study of Deoxycholic Acid Injection

                            Details : Deoxycholic acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Submental Fullness.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 10, 2013

                            Lead Product(s) : Deoxycholic Acid

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Allergan Aesthetics

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deoxycholic Acid

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneo...

                            Details : Deoxycholic acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Submental Fullness.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 07, 2012

                            Lead Product(s) : Deoxycholic Acid

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth